U.S. patent application number 17/304888 was filed with the patent office on 2021-10-28 for liquid neurotoxin formulation stabilized with tryptophan or tyrosine.
This patent application is currently assigned to IPSEN BIOPHARM LIMITED. The applicant listed for this patent is IPSEN BIOPHARM LIMITED. Invention is credited to Barbro AGREN, Emilia EDSTROM, Anna FRIIS, Ann GURELL, Anders JARSTAD, Andrew PICKETT, Ulf STAHL.
Application Number | 20210330765 17/304888 |
Document ID | / |
Family ID | 1000005695647 |
Filed Date | 2021-10-28 |
United States Patent
Application |
20210330765 |
Kind Code |
A1 |
JARSTAD; Anders ; et
al. |
October 28, 2021 |
LIQUID NEUROTOXIN FORMULATION STABILIZED WITH TRYPTOPHAN OR
TYROSINE
Abstract
The invention relates to stable liquid neurotoxin formulations
which are free of animal proteins, comprising a surfactant, an
amino acid selected from tryptophan and tyrosine, a buffer
comprising sodium, chloride and phosphate ions, which have a pH
between 5.5 and 8, and which are stable for 2 months. These
compositions are suitable for use in therapy and in particular for
administration to a patient to achieve a desired therapeutic or
aesthetic effect. The invention also relates to the use of an amino
acid selected from tryptophan and tyrosine to protect a
proteinaceous neurotoxin from degradation in a liquid composition
which is free of animal derived proteins.
Inventors: |
JARSTAD; Anders; (Uppsala,
SE) ; FRIIS; Anna; (Uppsala, SE) ; STAHL;
Ulf; (Uppsala, SE) ; GURELL; Ann; (Stockholm,
SE) ; AGREN; Barbro; (Mattmar, SE) ; EDSTROM;
Emilia; (Uppsala, SE) ; PICKETT; Andrew;
(Uppsala, SE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
IPSEN BIOPHARM LIMITED |
Wrexham |
|
GB |
|
|
Assignee: |
IPSEN BIOPHARM LIMITED
Wrexham
GB
|
Family ID: |
1000005695647 |
Appl. No.: |
17/304888 |
Filed: |
June 28, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16304986 |
Nov 27, 2018 |
|
|
|
PCT/EP2017/062785 |
May 26, 2017 |
|
|
|
17304888 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 8/19 20130101; A61Q
19/08 20130101; A61K 38/4893 20130101; A61K 9/0019 20130101; A61K
8/492 20130101; A61K 47/02 20130101; A61K 47/183 20130101; A61K
8/66 20130101; A61K 8/00 20130101; A61K 47/26 20130101; A61K 8/39
20130101 |
International
Class: |
A61K 38/48 20060101
A61K038/48; A61K 47/02 20060101 A61K047/02; A61K 47/18 20060101
A61K047/18; A61K 47/26 20060101 A61K047/26; A61K 8/39 20060101
A61K008/39; A61K 8/49 20060101 A61K008/49; A61K 8/66 20060101
A61K008/66; A61Q 19/08 20060101 A61Q019/08; A61K 9/00 20060101
A61K009/00; A61K 8/19 20060101 A61K008/19; A61K 8/00 20060101
A61K008/00 |
Foreign Application Data
Date |
Code |
Application Number |
May 27, 2016 |
EP |
2016062085 |
Claims
1. A liquid composition comprising a proteinaceous neurotoxin, a
surfactant, an amino acid selected from tryptophan and tyrosine, a
buffer comprising sodium, chloride and phosphate ions, wherein said
liquid composition has a pH between 5.5 and 8, wherein said
composition is free of animal derived proteins, and wherein said
liquid composition is stable over time.
2. A liquid composition according to claim 1, wherein said
surfactant is a non-ionic surfactant.
3. A liquid composition according to claim 2, wherein said
non-ionic surfactant is a polysorbate, preferably Polysorbate 20,
Polysorbate 60 or Polysorbate 80.
4. A liquid composition according to any one of claims 1 to 3,
wherein said amino acid is tryptophan, preferably L-tryptophan.
5. A liquid composition according to any one of claims 1 to 4,
wherein said buffer further comprises potassium ions.
6. A liquid composition according to any one of claims 1 to 5,
wherein said composition has a pH between 6.0 and 7.5.
7. A liquid composition according to any one of claims 1 to 6,
wherein no more than 30% loss in extracellular proteolytic activity
occurs over 2, 3, 6, 12, 18, 24 or 36 months at 5.degree. C.
8. A liquid composition according to any one of claims 1 to 7,
wherein said proteinaceous neurotoxin is a botulinum neurotoxin,
selected from a natural botulinum neurotoxin in complex form, a
high purity natural botulinum neurotoxin and a recombinant
botulinum neurotoxin.
9. A liquid composition according to claim 8, wherein said
botulinum neurotoxin is a recombinant botulinum neurotoxin selected
from a botulinum neurotoxin A, B, C, D, E, For G, a modified
botulinum neurotoxin and a chimeric botulinum neurotoxin.
10. A liquid composition according to any one of claims 1 to 9,
wherein said liquid composition comprises: 4 to 10000 LD50 units of
botulinum neurotoxin per mL, 0.001 to 15% v/v polysorbate, 0.1 to 5
mg/mL tryptophan, 10 to 500 mM NaCl, 1 to 50 mM KCl, 1 to 100 mM
Sodium phosphate, has a pH between 5.5 and 8, and is stable for 6
months at 5.degree. C.
11. A liquid composition according to claim 10, wherein said liquid
composition comprises: 10 to 2000 LD50 units of botulinum
neurotoxin per mL, 0.05 to 0.2% v/v polysorbate 80, 0.1 to 5 mg/mL
tryptophan, 25 to 300 mM NaCl, 1 to 10 mM KCl, 2 to 50 mM Sodium
phosphate, has a pH between 6.0 and 7.5, and is stable for 12
months at 5.degree. C.
12. A liquid composition according to any one of claims 1 to 11 for
use in therapy.
13. A liquid composition according to claim 12 for use in treating
or preventing muscular disorders, neuromuscular disorders,
neurological disorders, ophthalmological disorders, pain disorders,
psychological disorders, articular disorders, inflammatory
disorders, endocrine disorders or urological disorders.
14. Use of liquid composition according to any one of claims 1 to
11 in aesthetic medicine, for example for treating or preventing
skin wrinkles, in particular facial wrinkles such as facial frown
lines, wrinkles of the contour of the eye, glabellar frown lines,
downturned mouth, wrinkles of the neck (platysmal bands), wrinkles
of the chin (mentalis, peau d'orange, dimpled chin), forehead
lines, "scratched skin" wrinkles, nasal lift treatment or sleep
lines.
15. Use of an amino acid selected from tryptophan and tyrosine to
protect a proteinaceous neurotoxin from degradation in a liquid
composition which is free of animal derived proteins.
16. Use according to claim 15, wherein said amino acid is
tryptophan.
17. Use according to claim 15 or 16, wherein said proteinaceous
neurotoxin is a botulinum neurotoxin.
18. Use according to claim 15, wherein said amino acid is used in
combination with a surfactant and a buffer comprising sodium,
chloride and phosphate ions, and said liquid composition has a pH
between 5.5 and 8.
Description
[0001] The present invention relates to animal protein free liquid
neurotoxin formulations. In particular, the present invention
relates to animal protein free liquid botulinum neurotoxin
formulations stabilized with non proteinaceous excipients.
[0002] The neurotoxin formulations described herein are suitable
for use in therapy and in particular for administration to a
patient to achieve a desired therapeutic or aesthetic effect.
BACKGROUND OF THE INVENTION
[0003] Clostridial neurotoxins naturally produced by clostridial
strains are the most toxic biological agents known to date and at
the same time are powerful tools for the treatment of a number of
neuromuscular and endocrine disorders, including cervical dystonia,
spasticity, blepharospasm, hyperhidrosis or sialorrhea. They also
find uses in the aesthetic field for the smoothing of wrinkles.
[0004] In order to be suitable for use as a pharmaceutical product,
a neurotoxin composition must be such that it can be stored without
significant loss of neurotoxin activity.
[0005] In all currently approved formulations of botulinum
neurotoxins, an animal (including human) protein, usually human
serum albumin (HSA), is used as a stabiliser.
[0006] The presence of animal proteins such as HSA in
pharmaceutical compositions is however undesirable because of the
risk, even if low, of unwillingly transmitting animal borne
infectious agents such as prions to a patient.
[0007] Animal protein free botulinum toxin formulations have been
disclosed in the art. For example, WO0158472 describes lyophilized
compositions in which a polysaccharide, such as 2-hydroxyethyl
starch is used to stabilize a botulinum toxin. WO2005007185
describes compositions in which a surface active substance, and a
mixture of at least two amino acids selected from Glu and Gin or
Asp and Asn are used to stabilize a botulinum toxin.
[0008] Most prior art formulations are however not stable in liquid
form and are therefore stored in lyophilized or freeze-dried form.
Such formulations need to be reconstituted by the physician in a
sterile saline solution before administration to a patient. This
reconstitution step is associated with a loss of physician time, a
risk of a dilution error and also a risk of contamination during
the reconstitution process. The botulinum toxin provider must also
train the physicians in order to ensure that the reconstitution
step is performed adequately.
[0009] Liquid formulations are therefore advantageous as they
obviate the loss of time for the physician, the risk of a dilution
error, the contamination risk and the need for providing training
for the provider.
[0010] Liquid HSA-free formulations are described for example in
WO2006005910 which discloses liquid botulinum toxin formulations
comprising a surfactant, sodium chloride and a disaccharide.
WO2009008595 discloses liquid botulinum toxin formulations
comprising polysorbate 20 and methionine.
[0011] It is an objective of the present invention to provide
advantageous liquid animal protein free botulinum neurotoxin
formulations, which are suitable for storage and for use in
therapy. In particular, the stabilizing formulation should maintain
product stability, be free of animal proteins and also be suitable
for stabilising a neurotoxin which is free of complexing
proteins.
SUMMARY OF THE INVENTION
[0012] A first aspect of the present invention is a liquid
composition comprising or consisting essentially of a proteinaceous
neurotoxin, a surfactant, an amino acid selected from tryptophan
and tyrosine, a buffer comprising sodium, chloride and phosphate
ions, which has a pH between 5.5 and 8, which is stable over time
and which is free of animal derived proteins.
[0013] Another aspect is the use of the liquid compositions
according to the invention in therapy and/or in cosmetics.
[0014] A further aspect of the present invention is the use of an
amino acid selected from tryptophan and tyrosine to protect a
proteinaceous neurotoxin from degradation in a liquid composition
which is free of animal derived proteins.
DETAILED DESCRIPTION OF THE INVENTION
[0015] A first aspect of the present invention is a liquid
composition comprising or consisting essentially of a proteinaceous
neurotoxin, a surfactant, an amino acid selected from tryptophan
and tyrosine, a buffer comprising sodium, chloride and phosphate
ions, which has a pH between 5.5 and 8, which is stable over time
and which is free of animal derived proteins.
[0016] "Animal protein free" is to be understood as comprising no
protein of animal, including human, origin.
[0017] A neurotoxin is a substance that targets a nerve cell and
affects a neurological function. Proteinaceous neurotoxins include
botulinum toxins (BoNT) and tetanus toxin (TeNT). Preferably, the
proteinaceous neurotoxin is a botulinum neurotoxin.
[0018] Botulinum neurotoxins are 150 kDa metalloproteases that
consist in their active form of a 50 kDa light chain (L) and a 100
kDa heavy chain (H) linked by a disulfide bridge. The L chain is a
zinc-protease which intracellular{circumflex over ( )} cleaves one
of the SNARE (Soluble NSF Attachment Protein REceptor) proteins
involved in vesicle mediated neurotransmitter release, thereby
disrupting neurotransmitter mediated mechanisms. The heavy chain
encompasses two domains: an N-terminal 50 kDa translocation domain
(H.sub.N), and a C-terminal 50 kDa receptor-binding domain (He).
The H.sub.c domain of a botulinum neurotoxin comprises two distinct
structural features that are referred to as the H.sub.Cc and
H.sub.CN domains. Amino acid residues involved in receptor binding
are believed to be primarily located in the H.sub.Cc domain.
[0019] Botulinum neurotoxins have been classified in 7
antigenically distinct serotypes (A to G). Exemplary amino acid
sequences for each serotype are provided herein as SEQ ID NO 1 to
7.
[0020] For each of the sequences, the different domains can for
example be as follow.
TABLE-US-00001 Serotype L chain H.sub.N domain .sub.H O.sub.N
domain H.sub.CC domain BoNT/A 1-448 449-871 872-1110 1111-1296 (SEQ
ID NO 1) BoNT/B 1-440 441-858 859-1097 1098-1291 (SEQ ID NO 2)
BoNT/C 1-441 442-866 867-1111 1112-1291 (SEQ ID NO 3) BoNT/D 1-445
446-862 863-1098 1099-1276 (SEQ ID NO 4) BoNT/E 1-422 423-845
846-1085 1086-1252 (SEQ ID NO 5) BoNT/F 1-439 440-864 865-1105
1106-1274 (SEQ ID NO 6) BoNT/G 1-441 442-863 864-1105 1106-1297
(SEQ ID NO 7)
[0021] The skilled person will appreciate that there can be some
variation in each of the botulinum neurotoxin domains.
[0022] BoNTs act for example on neuromuscular nerve junctions by
preventing release of acetylcholine and thereby preventing muscular
contraction. Nerve terminal intoxication is reversible and its
duration varies for different BoNT serotypes.
[0023] Natural BoNTs are produced by Clostridium botulinum, and
other Clostridial species such as C. butyricum, C. baratii and C.
argentinense as part of multi-protein complexes that protect the
neurotoxin from proteolytic degradation. By "botulinum neurotoxin
in complex form" is meant a botulinum neurotoxin and one or more of
the proteins which are part in nature of such multi-protein
complexes (neurotoxin-associated proteins or "NAPs"). NAPs include
non-toxic non-hemagglutinin (NTN H) protein and hemagglutinin
proteins (HA-17, HA-33, and HA-70). By "high purity botulinum
neurotoxin" is meant a botulinum neurotoxin essentially free of
NAPs.
[0024] According to an embodiment of the invention, the botulinum
neurotoxin is a botulinum neurotoxin in complex form. According to
another embodiment, the botulinum neurotoxin is a high purity
botulinum neurotoxin.
[0025] Method for producing BoNTs through culture of natural
clostridial strains and purifying them either in complex form or
high purity form are well known in the art and are described for
example in Pickett, Andy. "Botulinum toxin as a clinical product:
manufacture and pharmacology." Clinical Applications of Botulinum
Neurotoxin. Springer New York, 2014. 7-49.
[0026] High purity or essentially pure botulinum neurotoxin can be
obtained from a protein complex comprising botulinum toxin for
example according to the method described in Current topics in
Microbiology and Immunology (1995), 195, p. 151-154.
[0027] Alternatively, high purity botulinum neurotoxin can be
produced by recombinant expression of a BoNT gene in a heterologous
host such as E. coli and purified therefrom.
[0028] Preferably, the proteinaceous neurotoxin is a botulinum
neurotoxin. According to an embodiment of the invention, the
botulinum neurotoxin is a botulinum neurotoxin in complex form.
According to another embodiment, the botulinum neurotoxin is a high
purity botulinum neurotoxin.
[0029] According to an embodiment of the invention, the botulinum
neurotoxin is a botulinum neurotoxin purified from its natural
clostridial strain. According to another embodiment, botulinum
neurotoxin is a botulinum neurotoxin produced recombinantly in a
heterologous host such as E. COIL
[0030] According to the present invention, the Botulinum neurotoxin
can be a BoNT of serotype A, B, C, D, E, For G.
[0031] According to the present invention, a botulinum neurotoxin
can be a modified botulinum neurotoxin. According to the present
invention, a "modified BoNT" is a BoNT which has an amino acid
sequence which has at least 50% sequence identity with SEQ ID NO 1,
2, 3, 4, 5, 6 or 7. Preferably, a modified BoNT has an amino acid
sequence which has at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%,
98% or 99% sequence identity with SEQ ID NO 1, 2, 3, 4, 5, 6 or 7.
Preferably, a modified BoNT is a BoNT whose amino acid sequence
differs from SEQ ID NO 1, 2, 3, 4, 5, 6 or 7 by less than 600, 400,
200, 150, 100, 50 or 20 amino acid substitutions, deletions or
additions, for example by 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino
acid substitutions, deletions or additions.
[0032] According to the present invention, a recombinant botulinum
neurotoxin can be a chimeric botulinum neurotoxin. According to the
present invention, a "chimeric BoNT" is constituted by an L,
H.sub.N, H.sub.c.sub.N, and H.sub.c.sub.c domain which do not all
belong to the same serotype. For example a chimeric BoNT can
consist of an L chain from one serotype and a full H chain
(H.sub.N, H.sub.c.sub.N, and H.sub.c.sub.c domains) from a
different serotype. A chimeric BoNT can also consist of an L chain
and an H.sub.N domain ("LH.sub.N") from one serotype and an H.sub.C
domain (H.sub.CN and H.sub.C.sub.c) from a different serotype. A
chimeric BoNT can also consist of an L chain and H.sub.N and
H.sub.CN domains ("extended LH.sub.N") from one serotype and an
H.sub.C.sub.c domain from a different serotype.
[0033] According to the invention a Light chain domain (L) can have
an amino acid sequence which has at least 50%, preferably at least
60%, 70%, 80%, 90% or 95% sequence identity to one of the following
amino acid sequences and which retains the ability to cleave one of
the SNARE proteins involved in vesicle mediated neurotransmitter
release: [0034] Amino acid 1-448 of SEQ ID NO:I [0035] Amino acid
1-440 of SEQ ID NO:2 [0036] Amino acid 1-441 of SEQ ID NO:3 [0037]
Amino acid 1-445 of SEQ ID NO:4 [0038] Amino acid 1-422 of SEQ ID
NO:5 [0039] Amino acid 1-439 of SEQ ID NO:6 [0040] Amino acid 1-441
of SEQ ID NO:7
[0041] According to the invention an H.sub.N domain can have an
amino acid sequence which has at least 50%, preferably at least
60%, 70%, 80%, 90% or 95% sequence identity to one of the following
amino acid sequences and which retains a translocation ability:
[0042] Amino acid 449-871 of SEQ ID NO:I [0043] Amino acid 441-858
of SEQ ID NO:2 [0044] Amino acid 442-866 of SEQ ID NO:3 [0045]
Amino acid 446-862 of SEQ ID NO:4 [0046] Amino acid 423-845 of SEQ
ID NO:5 [0047] Amino acid 440-864 of SEQ ID NO:6 [0048] Amino acid
442-863 of SEQ ID NO:7
[0049] According to the invention an H.sub.c domain can have an
amino acid sequence which has at least 50%, preferably at least
60%, 70%, 80%, 90% or 95% sequence identity to one of the following
amino acid sequences and which retains the ability to bind to a
neuromuscular cell: [0050] Amino acid 872-1296 of SEQ ID NO:I
[0051] Amino acid 859-1291 of SEQ ID NO:2 [0052] Amino acid
867-1291 of SEQ ID NO:3 [0053] Amino acid 863-1276 of SEQ ID NO:4
[0054] Amino acid 846-1252 of SEQ ID NO:5 [0055] Amino acid
865-1274 of SEQ ID NO:6 [0056] Amino acid 864-1297 of SEQ ID
NO:7
[0057] According to the invention an H.sub.Cc domain can have an
amino acid sequence which has at least 50%, preferably at least
60%, 70%, 80%, 90% or 95% sequence identity to one of the following
amino acid sequences and which retains the ability to bind to a
neuromuscular cell: [0058] Amino acid 1111-1296 of SEQ ID NO:I
[0059] Amino acid 1098-1291 of SEQ ID NO:2 [0060] Amino acid
1112-1291 of SEQ ID NO:3 [0061] Amino acid 1099-1276 of SEQ ID NO:4
[0062] Amino acid 1086-1252 of SEQ ID NO:5 [0063] Amino acid
1106-1274 of SEQ ID NO:6 [0064] Amino acid 1106-1297 of SEQ ID
NO:7
[0065] The above-identified reference sequences should be
considered as a guide, as slight variations may occur according to
sub-serotypes.
[0066] The "percent sequence identity" between two or more nucleic
acid or amino acid sequences is a function of the number of
identical nucleotides/amino acids at identical positions shared by
the aligned sequences. Thus, % identity may be calculated as the
number of identical nucleotides/amino acids at each position in an
alignment divided by the total number of nucleotides/amino acids in
the aligned sequence, multiplied by 100. Calculations of % sequence
identity may also take into account the number of gaps, and the
length of each gap that needs to be introduced to optimize
alignment of two or more sequences. Sequence comparisons and the
determination of percent identity between two or more sequences can
be carried out using specific mathematical algorithms, such as
BLAST, which will be familiar to a skilled person.
[0067] Surfactants (or surface active agents) are compounds that
are able to lower the surface tension between a liquid and a solid
or between two liquids. Surfactants can be non-ionic, anionic,
cationic or amphoteric. In the compositions according to the
invention, the surfactant is preferably a non-ionic surfactant.
Non-ionic surfactants include Polyoxyethylene glycol alkyl ethers,
such as Octaethylene glycol monododecyl ether or Pentaethylene
glycol monododecyl ether; Polyoxypropylene glycol alkyl ethers;
Glucoside alkyl ethers, such as Decyl glucoside, Lauryl glucoside
or Octyl glucoside; Polyoxyethylene glycol octylphenol ethers, such
as Triton X-100; Polyoxyethylene glycol alkylphenol ethers, such as
Nonoxynol-9; Glycerol alkyl esters, such as Glyceryl laurate;
Polyoxyethylene glycol sorbitan alkyl esters, such as Polysorbates;
Sorbitan alkyl esters, such as Spans; Cocamide MEA, cocamide DEA;
Dodecyldimethylamine oxide; Block copolymers of polyethylene glycol
and polypropylene glycol, such as Poloxamers; Polyethoxylated
tallow amine (POEA).
[0068] According to a preferred embodiment, the liquid composition
according to the invention comprises a non-ionic surfactant which
is a polysorbate, preferably polysorbate 20 (PS20), polysorbate 60
(PS60) or polysorbate 80 (PS80). Most preferably, the non-ionic
surfactant is PS80. When the surfactant is a polysorbate, its
concentration is preferably from 0.001% to 15% v/v, more preferably
from 0.005 to 2% v/v, more preferably still from 0.01 to 1% for
example 0.01, 0.05, 0.1, 0.2, 0.5 or 1% v/v. According to one
embodiment, the surfactant is PS80 at a concentration from 0.05 to
0.2% v/v, for example about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10,
0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19 or 0.20%
v/v.
[0069] PS20 has a density of approximately 1.1 g/mL. PS60 has a
density of approximately 1.044 g/mL. PS80 has a density of
approximately 1.06 to 1.09 g/mL.
[0070] Polysorbates are believed to form micelles and prevent
adsorption of proteins to surfaces and protein aggregation. Without
wishing to be bound by theory, it is believed that upon
degradation/oxidation, polysorbates may form peroxides and acids
that may have an effect on protein stability. Therefore, it is
considered preferable that the concentration of polysorbate be as
low as possible in the formulation of the product. It is therefore
considered preferable that the concentration of polysorbate should
not exceed 200 times its critical micellar concentration (CMC),
more preferably it should not exceed 100, 50, 20, 10 or 5 times its
CMC.
[0071] For PS20 (Mw 1227.5 g/mol), the CMC is approximatively
8.times.10.sup.-5 M at 21.degree. C., i.e. approximately 0.01%
w/v.
[0072] For PS60 (Mw 1309 g/mol), the CMC is approximately
21.times.10.sup.-6 M at 21.degree. C., i.e. approximately 0.003%
w/v.
[0073] For PS80 (Mw 1310 g/mol), the CMC is approximatively
12.times.10.sup.-6 M at 21.degree. C., i.e. approximately 0.002%
w/v.
[0074] According to a preferred embodiment, the polysorbate
concentration is between 1 and 200 times its CMC at a given
temperature, for example about 21.degree. C., preferably between 2
and 100 times its CMC, for example about 20 or 50 times its
CMC.
[0075] The liquid composition according to the invention comprises
an amino acid which is tryptophan or tyrosine. Without willing to
be bound by theory, it is hypothesized that tryptophan or tyrosine
can prevent oxidation of the active protein which would render it
non-functional. Indeed, it is thought that the amino acid added in
molar excess over the neurotoxin will be oxidized in the first
place, saving the neurotoxin. It is also hypothesized that
tryptophan or tyrosine can neutralize reactive degradation products
of surfactants such as polysorbates.
[0076] Preferably the amino acid is tryptophan. More preferably,
the amino acid is L-tryptophan.
[0077] The amino acid concentration is preferably from about 0.1 to
5 mg/mL, more preferably between 0.1 and 5 mg/mL, from 0.25 and 3
mg/mL for example about 0.25, 0.5, 1, 1.5, 2 or 3 mg/mL.
[0078] The composition according to the invention comprises a
buffer which comprises sodium, chloride and phosphate ions. The
inventors indeed surprisingly found that buffers without sodium,
chloride and phosphate ions lowered the stability of the toxin.
Preferably the buffer also comprises potassium ions.
[0079] The buffer can for example be obtained by combining sodium
chloride, potassium chloride and sodium phosphate salts. The sodium
chloride concentration is preferably from 10 to 500 mM, preferably
from about 25 to 300 mM, for example about 25, 50, 75, 100, 140,
150, 200, 250 or 300 mM.
[0080] The sodium phosphate concentration is preferably from 1 to
100 mM, preferably from 2 to 50 mM, for example about 2, 5, 10, 20,
30, 40 or 50 mM.
[0081] The potassium chloride concentration is preferably from 1 to
50 mM, preferably from 1 to 10 mM for example about 1, 2, 3, 4, 5
or 10 mM.
[0082] The composition according to the invention has a pH between
5.5 and 8. According to a preferred embodiment, the pH is between
6.0 and 7.5, for example about 6.3, 6.35, 6.4, 6.45, 6.5, 6.55,
6.6, 6.65, 6.7, 6.75, 6.8, 6.85, 6.9, 6.95, 7.0, 7.05, 7.1, 7.15,
7.2, 7.25, 7.3, 7.35, 7.4, 7.45 or 7.5. Preferably the pH is within
one unit from physiological pH (which is around 7.4).
[0083] The composition according to the invention is liquid. The
composition preferably comprises an aqueous diluent, more
preferably water, for example sterile water, water for injection,
purified water, sterile water for injection.
[0084] Preferably the formulation is isotonic and is suitable for
injection to a patient, in particular a human patient.
[0085] The quantity of botulinum neurotoxin is commonly expressed
in mouse LD50 (lethal dose 50) units, defined as the median lethal
intraperitoneal dose in mice.
[0086] The mouse LD50 (MLD50) unit for botulinum toxins is not a
standardised unit. Indeed, assays used by different manufacturers
of marketed toxins differ in particular in the choice of dilution
buffer. For example the test used for Dysport uses gelatine
phosphate buffer, whereas the assay used for BOTOX.RTM. uses saline
as a diluent. It is believed that gelatine buffers protect the
toxin at the high dilutions used in LD50 assays. In contrast the
use of saline as a diluent is thought to lead to some loss of
potency. This could explain why when tested with the Dysport.RTM.
assay, one BOTOX.RTM. unit is equivalent to approximately three
units of Dysport (Straughan, D. W., 2006, ATLA 34(3), 305-313;
Hambleton and Pickett, Hambleton, P., and A. M. Pickett., 1994,
Journal of the Royal Society of Medicine 87.11: 719).
[0087] Preferably, the dilution buffer used to determine the mouse
LD50 is a gelatine phosphate buffer. For example, the mouse LD50
can be determined as described in Hambleton, P. et al. Production,
purification and toxoiding of Clostridium botulinum type A toxin.
Eds. G. E Jr Lewis, and P. s. Angel. Academic Press, Inc., New
York, USA, 1981, p. 248. Briefly, botulinum toxin samples are
serially diluted in 0.2% (w/v) gelatine 0.07M Na2HP04 buffer at pH
6.5. Groups of mice (eg 4 to 8 mice per group) weighing about 20 g
are injected intraperitoneally with a sample of diluted toxin (for
example 0.5 ml per animal). Dilution groups, for example 5 dilution
groups, are selected to span the 50% lethality dose. The mice are
observed for up to 96 hours and the mouse lethal dose 50 (MLD50) is
estimated.
[0088] The composition according to the invention preferably
comprises from 4 to 10000 LD50 units of botulinum neurotoxin per
mL, more preferably from 10 to 2000 LD50 units of botulinum
neurotoxin per mL, for example 20, 30, 40, 50, 75, 100, 200, 300,
400, 500, 600, 700, 800, 900, 1000 or 1500 LD50 units of botulinum
neurotoxin per mL.
[0089] The quantity of botulinum neurotoxin can also be expressed
in ng. The composition according to the invention preferably
comprises from about 0.01 to 75 ng of botulinum neurotoxin per mL,
more preferably from about 0.03 to 20 ng botulinum neurotoxin per
mL, more preferably still from about 0.1 to 15 ng botulinum
neurotoxin per mL, for example about 0.15, 0.3, 0.5, 0.75, 1, 2, 3,
4, 5, 6, 7, 8, 9 or 10 ng botulinum neurotoxin per mL.
[0090] The formulation according to the invention is animal protein
free. In particular, the compositions according to the invention
comprise no albumin, and in particular no human serum albumin.
Preferably, the composition according to the invention is animal
product free, meaning that they comprise no constituent of animal
(including human) origin. Preferably, the composition according to
the invention comprises no protein other than the proteinaceous
neurotoxin. According to another embodiment, the composition
according to the invention comprises no protein other than the
proteinaceous neurotoxin and one or more NAPs
(neurotoxin-associated proteins). For the sake of doubt, it is
noted amino acids are not proteins.
[0091] According to an embodiment of the invention, the composition
comprises no saccharides, including no monosaccharides, no
disaccharides and no polysaccharides.
[0092] The liquid composition according to the invention is stable
over time. For example, it is stable for 2 months at 2 to 8.degree.
C. According to one embodiment, it is stable for 3 months at 2 to
8.degree. C., for example at 5.degree. C. According to a preferred
embodiment, it is stable for 6 months at 2 to 8.degree. C., for
example at 5.degree. C. According to one embodiment, it is stable
for 12 months at 2 to 8.degree. C., for example at 5.degree. C.
According to one embodiment, it is stable for 18 months at 2 to
8.degree. C., for example at 5.degree. C. According to one
embodiment, it is stable for 24 months at 2 to 8.degree. C., for
example at 5.degree. C. According to one embodiment, it is stable
for 36 months at 2 to 8.degree. C., for example at 5.degree. C.
According to one embodiment, it is stable for 3 months at room
temperature, for example at 25.degree. C. According to one
embodiment, it is stable for 6 months at room temperature, for
example at 25.degree. C. According to one embodiment, it is stable
for 2 months at 37.degree. C.
[0093] The liquid composition according to the invention is
preferably stored at a temperature between 0.degree. and 30.degree.
C. In a preferred embodiment it is stored at 2-8.degree. C., for
example at 5.degree. C. In another embodiment, it is stored at room
temperature. Preferably it is not frozen.
[0094] Stability can be assessed through comparison of the activity
of the botulinum neurotoxin over time. Activity of the botulinum
neurotoxin may refer to the ability of the activity of the
botulinum neurotoxin to bind to its target receptor on a cell, to
translocate the light chain into a cell, and/or to cleave its
target SNARE protein.
[0095] Methods for measuring Botulinum neurotoxin activity are well
known in the art. Botulinum neurotoxin activity can be assessed for
example by using a mouse lethality assay (LD50) as described above,
a muscle tissue based assay such as the mouse phrenic nerve
hemidiaphragm assay (for example as described in Bigalke, H. and
Rummel A., Toxins 7.12 (2015):4895-4905), a cell based assay (for
example as described in WO201349508 or in WO2012166943) or an
extracellular proteolytic activity assay such as BoTest.RTM.
(Botulinum Neurotoxin Detection Kit available from BioSentinel
Inc.).
[0096] Preferably, a composition according to the invention is
considered stable if there is no more than a given percentage of
loss of activity over a given period of time and at a given
temperature.
[0097] According to one embodiment, a composition according to the
invention is considered stable if there is no more than 30% loss in
extracellular proteolytic activity over 3, 6, 12, 18, 24 or 36
months at 2 to 8.degree. C., for example no more than 30% loss in
extracellular proteolytic activity over 6 months at 5.degree. C.
Preferably, a composition according to the invention is considered
stable if there is no more than 20% loss in extracellular
proteolytic activity over 3 months at 5.degree. C., more preferably
over 6, 12, 18, 24 or 36 months at 5.degree. C. According to
another embodiment, a composition according to the invention is
considered stable if there is no more than 40% loss in
extracellular proteolytic activity over 3 months at room
temperature, for example at 25.degree. C. Preferably, a composition
according to the invention is considered stable if there is no more
than 30% loss in extracellular proteolytic activity over 3 months
at 25.degree. C., more preferably over 6 months at 25.degree. C.
According to another embodiment, a composition according to the
invention is considered stable if there is no more than 50% loss in
extracellular proteolytic activity over 2 months at 37.degree. C.
Extracellular proteolytic activity can be measured with the
BoTest.RTM. assay.
[0098] According to one embodiment, a composition according to the
invention is considered stable if there is no more than 30% loss in
MLD50 units over 2, 3, 6, 12, 18, 24 or 36 months at 2 to 8.degree.
C., for example no more than 30% loss in MLD50 units over 6 months
at 5.degree. C. Preferably, a composition according to the
invention is considered stable if there is no more than 20% loss in
MLD50 units over 2 months at 5.degree. C., more preferably over 3,
6, 12, 18, 24 or 36 months at 5.degree. C. According to another
embodiment, a composition according to the invention is considered
stable if there is no more than 40% loss in MLD50 units over 2 or 3
months at room temperature, for example at 25.degree. C.
Preferably, a composition according to the invention is considered
stable if there is no more than 30% loss in MLD50 units over 3
months at 25.degree. C., more preferably over 6 months at
25.degree. C. According to another embodiment, a composition
according to the invention is considered stable if there is no more
than 50% loss in MLD50 units over 2 months at 37.degree. C. MLD50
units can be measured as indicated above.
[0099] The liquid compositions according to the invention can be
stored in sealed vials or syringes, for example glass vials or
syringes, preferably type 1 (or "body neutral") glass vials or
syringes. Preferably there is no or very little oxygen in the vial
or syringe. The vials or syringes can for example be filled in an
atmosphere with an oxygen below 100 ppm, preferably below 50 ppm,
and nitrogen gas can be used as a protective atmosphere in the
vials. When glass vials are used, they can for example be capped
with chlorobutyl or bromobutyl rubber stoppers, which can be
FluroTec.RTM. coated stoppers. Preferably, the liquid compositions
according to the invention are stored in glass vials capped with
FluroTec.RTM. coated stoppers.
[0100] According to one embodiment, a liquid composition according
to the invention comprises or consists essentially of: [0101] 4 to
10000 LD50 units of botulinum neurotoxin per mL, [0102] 0.001 to
15% v/v polysorbate, [0103] 0.1 to 5 mg/mL tryptophan, [0104] 10 to
500 mM NaCl, [0105] 1 to 50 mM KCl, [0106] 1 to 100 mM Sodium
phosphate, has a pH between 5.5 and 8, and is stable for 6 months
at 5.degree. C.
[0107] According to one embodiment, a liquid composition according
to the invention comprises or consists essentially of: [0108] 10 to
2000 LD50 units of botulinum neurotoxin per mL, [0109] 0.005 to 2%
v/v polysorbate, [0110] 0.1 to 5 mg/mL tryptophan, [0111] 25 to 300
mM NaCl, [0112] 1 to 10 mM KCl, [0113] 2 to 50 mM Sodium phosphate,
has a pH between 6.0 and 7.5, and is stable for 12 months at
5.degree. C.
[0114] According to one embodiment, a liquid composition according
to the invention comprises or consists essentially of: [0115] 10 to
2000 LD50 units of botulinum neurotoxin per mL, [0116] 0.05 to 0.2%
v/v polysorbate 80, [0117] 0.1 to 5 mg/mL tryptophan, [0118] 25 to
300 mM NaCl, [0119] 1 to 10 mM KCl, [0120] 2 to 50 mM Sodium
phosphate, [0121] has a pH between 6.0 and 7.5, and is stable for
12 months at 5.degree. C.
[0122] According to one embodiment, a liquid composition according
to the invention comprises or consists essentially of: [0123]
Botulinum neurotoxin A, [0124] 0.2% v/v polysorbate 80, [0125] 1
mg/mL tryptophan [0126] 140 mM NaCl, [0127] 3 mM KCl, [0128] 10 mM
Sodium phosphate, [0129] wherein the pH of said composition is
approximately 6.6.
[0130] According to another embodiment, a liquid composition
according to the invention comprises or consists essentially of:
[0131] Botulinum neurotoxin A, [0132] 0.04% v/v polysorbate 80,
[0133] 1 mg/mL tryptophan [0134] 140 mM NaCl, [0135] 3 mM KCl,
[0136] 10 mM Sodium phosphate, [0137] wherein the pH of said
composition is approximately 6.9.
[0138] According to another embodiment, a liquid composition
according to the invention comprises or consists essentially of:
[0139] Botulinum neurotoxin B, [0140] 0.25% v/v polysorbate 20,
[0141] 4 mg/mL tryptophan [0142] 140 mM NaCl, [0143] 3 mM KCl,
[0144] 10 mM Sodium phosphate, [0145] wherein the pH of said
composition is approximately 7.4.
[0146] According to another embodiment, a liquid composition
according to the invention comprises or consists essentially of:
[0147] Botulinum neurotoxin A, [0148] 0.01% v/v polysorbate 80,
[0149] 0.25 mg/mL tryptophan [0150] 255 mM NaCl, [0151] 2 mM Sodium
phosphate, [0152] wherein the pH of said composition is
approximately 7.2.
[0153] According to another embodiment, a liquid composition
according to the invention comprises or consists essentially of:
[0154] Botulinum neurotoxin A, [0155] 0.01% v/v polysorbate 80,
[0156] 0.25 mg/mL tryptophan [0157] 255 mM NaCl, [0158] 10 mM KCl,
[0159] 50 mM Sodium phosphate, [0160] wherein the pH of said
composition is approximately 6.3.
[0161] According to another embodiment, a liquid composition
according to the invention comprises or consists essentially of:
[0162] Botulinum neurotoxin A, [0163] 1% v/v polysorbate 80, [0164]
0.25 mg/mL tryptophan [0165] 255 mM NaCl, [0166] 50 mM Sodium
phosphate, [0167] wherein the pH of said composition is
approximately 6.3.
[0168] According to another embodiment, a liquid composition
according to the invention comprises or consists essentially of:
[0169] Botulinum neurotoxin A, [0170] 1% v/v polysorbate 80, [0171]
3 mg/mL tryptophan [0172] 255 mM NaCl, [0173] 10 mM KCl, [0174] 50
mM Sodium phosphate, [0175] wherein the pH of said composition is
approximately 7.2.
[0176] According to another embodiment, a liquid composition
according to the invention comprises or consists essentially of:
[0177] Botulinum neurotoxin A, [0178] 0.1% v/v polysorbate 80,
[0179] 1.625 mg/mL tryptophan [0180] 140 mM NaCl, [0181] 3 mM KCl,
[0182] 10 mM Sodium phosphate, [0183] wherein the pH of said
composition is approximately 6.75.
[0184] According to another embodiment, a liquid composition
according to the invention comprises or consists essentially of:
[0185] Botulinum neurotoxin A, [0186] 0.01% v/v polysorbate 80,
[0187] 1 mg/mL tryptophan [0188] 140 mM NaCl, [0189] 3 mM KCl,
[0190] 10 mM Sodium phosphate, [0191] wherein the pH of said
composition is approximately 6.75.
[0192] According to another embodiment, a liquid composition
according to the invention comprises or consists essentially of:
[0193] Botulinum neurotoxin A, [0194] 0.1% v/v polysorbate 80,
[0195] 1 mg/mL tryptophan [0196] 140 mM NaCl, [0197] 3 mM KCl,
[0198] 10 mM Sodium phosphate, [0199] wherein the pH of said
composition is approximately 6.75.
[0200] According to another embodiment, a liquid composition
according to the invention comprises or consists essentially of:
[0201] Botulinum neurotoxin A, [0202] 1% v/v polysorbate 80, [0203]
1 mg/mL tryptophan [0204] 140 mM NaCl, [0205] 3 mM KCl, [0206] 10
mM Sodium phosphate, [0207] wherein the pH of said composition is
approximately 6.75.
[0208] According to another embodiment, a liquid composition
according to the invention comprises or consists essentially of:
[0209] Botulinum neurotoxin B, [0210] 15% v/v polysorbate 20,
[0211] 1 mg/mL tryptophan [0212] 140 mM NaCl, [0213] 3 mM KCl,
[0214] 10 mM Sodium phosphate, [0215] wherein the pH of said
composition is approximately 7.4.
[0216] According to another embodiment, a liquid composition
according to the invention comprises or consists essentially of:
[0217] Botulinum neurotoxin B, [0218] 15% v/v polysorbate 20,
[0219] 4 mg/mL tryptophan [0220] 140 mM NaCl, [0221] 3 mM KCl,
[0222] 10 mM Sodium phosphate, [0223] wherein the pH of said
composition is approximately 7.4.
[0224] According to another embodiment, a liquid composition
according to the invention comprises or consists essentially of:
[0225] Botulinum neurotoxin B, [0226] 0.25% v/v polysorbate 20,
[0227] 4 mg/mL tryptophan [0228] 140 mM NaCl, [0229] 3 mM KCl,
[0230] 10 mM Sodium phosphate,
[0231] wherein the pH of said composition is approximately 7.4.
[0232] Another aspect is the use of the liquid compositions
according to the invention in therapy. The liquid compositions
according to the invention can be used in therapy to treat or
prevent muscular disorders, neuromuscular disorders, neurological
disorders, ophtalmological disorders, pain disorders, psychological
disorders, articular disorders, inflammatory disorders, endocrine
disorders or urological disorders.
[0233] For example, the liquid compositions according to the
invention can be used for treating or preventing a disease,
condition or syndrome selected from the following: [0234]
ophtalmological disorders selected from the group consisting of
blepharospasm, strabismus (including restrictive or myogenic
strabismus), amblyopia, oscillopsia, protective ptosis, therapeutic
ptosis for corneal protection, nystagmus, estropia, diplopia,
entropion, eyelid retraction, orbital myopathy, heterophoria,
concomitant misalignment, nonconcomitant misalignment, primary or
secondary esotropia or exotropia, internuclear ophthalmoplegia,
skew deviation, Duane's syndrome and upper eyelid retraction;
[0235] movement disorders including hemifacial spasm, torticollis,
spasticity of the child or of the adult (e.g. in cerebral palsy,
post-stroke, multiple sclerosis, traumatic brain injury or spinal
cord injury patients), idiopathic focal dystonias, muscle
stiffness, Writer's cramp, hand dystonia, VI nerve palsy,
oromandibular dystonia, head tremor, tardive dyskinesia, tardive
dystonia, occupational cramps (including musicians' cramp), facial
nerve palsy, jaw closing spasm, facial spasm, synkinesia, tremor,
primary writing tremor, myoclonus, stiff-person-syndrome, foot
dystonia, facial paralysis,
painful-arm-and-moving-fingers-syndrome, tic disorders, dystonic
tics, Tourette's syndrome, neuromyotonia, trembling chin, lateral
rectus palsy, dystonic foot inversion, jaw dystonia, Rabbit
syndrome, cerebellar tremor, Iii nerve palsy, palatal myoclonus,
akasthesia, muscle cramps, IV nerve palsy, freezing-of-gait,
extensor truncal dystonia, post-facial nerve palsy synkinesis,
secondary dystonia, Parkinson's disease, Huntington's chorea,
epilepsy, off period dystonia, cephalic tetanus, myokymia and
benign cramp-fasciculation syndrome; [0236] otorhinolaryngological
disorders including spasmodic dysphonia, otic disorders, hearing
impairment, ear click, tinnitus, vertigo, Meniere's disease,
cochlear nerve dysfunction, stuttering, cricopharyngeal dysphagia,
bruxism, closure of larynx in chronic aspiration, vocal fold
granuloma, ventricular dystonia, ventricular dysphonia, mutational
dysphonia, trismus, snoring, voice tremor, aspiration, tongue
protrusion dystonia, palatal tremor, deep bite of lip and laryngeal
dystonia; First Bite Syndrome; [0237] gastrointestinal disorders
including achalasia, anal fissure, constipation, temperomandibular
joint dysfunction, sphincter of Oddi dysfunction, sustained
sphincter of Oddi hypertension, intestinal muscle disorders,
puborectalis syndrome, anismus, pyloric spasm, gall bladder
dysfunction, gastrointestinal or oesophageal motility dysfunction,
diffuse oesophageal spasm and gastroparesis; [0238] urogenital
disorders including detrusor sphincter dyssynergia, detrusor
hyperreflexia, neurogenic bladder dysfunction (e.g. in Parkinson's
disease, spinal cord injury, stroke or multiple sclerosis
patients), overactive bladder, neurogenic detrusor overactivity,
bladder spasms, urinary incontinence, urinary retention,
hypertrophied bladder neck, voiding dysfunction, interstitial
cystitis, vaginismus, endometriosis, pelvic pain, prostate gland
enlargement (Benign Prostatic Hyperplasia), prostatodynia, prostate
cancer and priapism; [0239] dermatological disorders including
cutaneous cell proliferative disorders, skin wounds, psoriasis,
rosacea, acne; rare hereditary skin disorders such as Fox-Fordyce
syndrome or Hailey-Hailey disease; keloid and hypertrophic scar
reduction; pore size reduction; inflammatory conditions of the
skin; painful inflammatory conditions of the skin; [0240] pain
disorders including back pain (upper back pain, lower back pain),
myofascial pain, tension headache, fibromyalgia, painful syndromes,
myalgia, migraine, whiplash, joint pain, post-operative pain, pain
not associated with a muscle spasm and pain associated with smooth
muscle disorders; [0241] inflammatory disorders including
pancreatitis, neurogenic inflammatory disorders (including gout,
tendonitis, bursitis, dermatomyositis and ankylosing spondylitis);
[0242] secretory disorders such as excessive gland secretions,
hyperhidrosis (including axillary hyperhidrosis, palmar
hyperhidrosis and Frey's syndrome), hypersalivation, sialorrhoea,
bromhidrosis, mucus hypersecretion, hyperlacrimation, holocrine
gland dysfunction; excess sebum secretion; [0243] respiratory
disorders including rhinitis (including allergic rhinitis), COPD,
asthma and tuberculosis; [0244] hypertrophic disorders including
muscle enlargement, masseteric hypertrophy, acromegaly and
neurogenic tibialis anterior hypertrophy with myalgia; [0245]
articular disorders including tennis elbow (or epicondilytis of the
elbow), inflammation of joints, coxarthrosis, osteoarthritis,
rotator muscle cap pathology of the shoulder, rheumatoid arthritis
and carpal tunnel syndrome; [0246] endocrine disorders like type 2
diabetes, hyperglucagonism, hyperinsulinism, hypoinsulinism,
hypercalcemia, hypocalcemia, thyroid disorders (including Grave's
disease, thyroiditis, Hashimoto's thyroiditis, hyperthyroidism and
hypothyroidism), parathyroid disorders (including
hyperparathyroidism and hypoparathyroidism), Gushing's syndrome and
obesity; [0247] autoimmune diseases like systemic lupus
erythemotosus; [0248] proliferative diseases including
paraganglioma tumors, prostate cancer and bone tumors; [0249]
traumatic injuries including sports injuries, muscle injuries,
tendon wounds and bone fractures; and [0250] veterinary uses (e.g.
immobilisation of mammals, equine colic, animal achalasia or animal
muscle spasms).
[0251] The liquid compositions according to the invention can also
be used in aesthetic medicine (that is for improving cosmetic
appearance), in particular for treating or preventing skin
wrinkles, in particular facial wrinkles such as facial frown lines,
wrinkles of the contour of the eye, glabellar frown lines,
downturned mouth, wrinkles of the neck (platysmal bands), wrinkles
of the chin (mentalis, peau d'orange, dimpled chin), forehead
lines, "scratched skin" wrinkles, nasal lift treatment or sleep
lines. According to this aspect of the invention, the subject to be
treated or prevented for improving cosmetic appearance is
preferably not suffering from any of the disorders, conditions or
syndromes that are described above. More preferably, said subject
is a healthy subject (i.e. not suffering from any disease,
condition or syndrome).
[0252] The liquid compositions according to the invention can be
used in combination with another therapeutic compound. In one
embodiment the liquid compositions according to the invention is
administered in combination with an analgesic compound for treating
pain, in particular in combination with an opioid derivative such
as morphine as described in WO 2007/144493 the content of which is
herein incorporated by reference. In another embodiment, the liquid
compositions according to the invention is administered in
combination with hyaluronic acid, for example for treating prostate
cancer as described in WO 2015/0444416 the content of which is
herein incorporated by reference.
[0253] A further aspect of the present invention is the use of an
amino acid selected from tryptophan and tyrosine to protect a
proteinaceous neurotoxin from degradation in a liquid composition
which is free of animal derived proteins.
[0254] According to a preferred embodiment, the amino acid is
tryptophan, more preferably L-tryptophan.
[0255] Preferably, the proteinaceous neurotoxin is a botulinum
neurotoxin. According to an embodiment of the invention, the
botulinum neurotoxin is a botulinum neurotoxin in complex form.
According to another embodiment, the botulinum neurotoxin is a high
purity botulinum neurotoxin. According to an embodiment of the
invention, the botulinum neurotoxin is a botulinum neurotoxin
purified from its natural clostridial strain. According to another
embodiment, botulinum neurotoxin is a botulinum neurotoxin produced
recombinantly in a heterologous host such as E. COIL According to
the present invention, the Botulinum neurotoxin can be a BoNT of
serotype A, B, C, D, E, For G. According to the present invention,
a botulinum neurotoxin can be a modified botulinum neurotoxin as
described above. According to the present invention, a recombinant
botulinum neurotoxin can be a chimeric botulinum neurotoxin as
described above.
[0256] According to a preferred embodiment, the amino acid is used
in combination with a surfactant and a buffer comprising sodium,
chloride and phosphate ions, and the liquid composition has a pH
between 5.5 and 8. Preferably, the surfactant is a non-ionic
surfactant, more preferably a polysorbate, for example PS20, PS60
or PS80. Most preferably, the non-ionic surfactant is PS80.
Preferably, the buffer also comprises potassium ions. The buffer
can for example be obtained by combining sodium chloride, potassium
chloride and sodium phosphate salts. According to a preferred
embodiment, the pH is between 6.0 and 7.5, for example 6.3, 6.35,
6.4, 6.45, 6.5, 6.55, 6.6, 6.65, 6.7, 6.75, 6.8, 6.85, 6.9, 6.95,
7.0, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35, 7.4, 7.45 or 7.5.
Preferably the pH is within one unit from physiological pH (which
is around 7.4).
[0257] According to a preferred embodiment of the use according to
the invention, the liquid composition is stable for 2 months. For
example, it is stable for 2 months at 2 to 8.degree. C. According
to one embodiment, it is stable for 3 months at 2 to 8.degree. C.,
for example at 5.degree. C. According to a preferred embodiment, it
is stable for 6 months at 2 to 8.degree. C., for example at
5.degree. C. According to one embodiment, it is stable for 12
months at 2 to 8.degree. C., for example at 5.degree. C. According
to one embodiment, it is stable for 18 months at 2 to 8.degree. C.,
for example at 5.degree. C. According to one embodiment, it is
stable for 24 months at 2 to 8.degree. C., for example at 5.degree.
C. According to one embodiment, it is stable for 36 months at 2 to
8.degree. C., for example at 5.degree. C. According to one
embodiment, it is stable for 3 months at room temperature, for
example at 25.degree. C. According to one embodiment, it is stable
for 6 months at room temperature, for example at 25.degree. C.
EXAMPLES
[0258] 1. Preparation of Stable Liquid Botulinum Toxin A
Formulations
[0259] Liquid botulinum toxin preparations containing 15 ng/mL of
highly purified BoNT/A, 15% v/v polysorbate 20, an amino acid
selected from tyrosine (Tyr), tryptophan (Trp) and cysteine (Cys)
or a mixture of methionine (Met), tyrosine (Tyr), tryptophan (Trp)
and cysteine (Cys) (Sigma Aldrich), and Phosphate Buffer Saline
(PBS from Calbiochem) (140 mM NaCl, 10 mM sodium phosphate and 3 mM
KCl at pH 7.4 at 25.degree. C.) were prepared, filtered using 0.22
.mu.m PVDF (polyvinylidenflourid) filters and stored in siliconized
2 mL glass syringes for 6 days at 40.degree. C., after which a
potency test was performed for each preparation.
[0260] For the potency test, the syringes containing the
preparations were emptied in 2 mL glass vials (Chromacol, Gold)
with lids containing PTFE treated rubber septa (Chromacol) or in
1.7 mL plastic micro centrifuge tubes (Axygen, Maximum Recovery)
which both have low protein adsorption properties. The preparations
were subsequently diluted using 0.9% NaCl solution with 3% human
serum albumin (HSA). For each preparation, 50 .mu.L of sample was
injected into the Gastrocnemius muscle of mice on the same day as
the dilution was performed. The mice were monitored for 3 days and
the degree of paralysis was recorded.
[0261] The results are shown in table 1.
TABLE-US-00002 TABLE 1 an accelerated storage test (6 days at
40.degree. C.) of amino acid additions on BoNT/A stability.
Paralysis results in mice: - = not analysed, WN = without note, PA
= paralysis and .dagger. = death. Formulation Potency test Potency
rating Buffer BoNT/ Amino Dilution Inj. Day Day Day 3 A acid in 0.9
Dose 1 2 conc. NaCl (ng) with 3% HSA (times) PBS pH 15 ng/ Trp 0.25
2 x 0.25 -- -- WN 7.4 15% mL mg/mL + 20 x 0.025 -- -- WN poly- Cys
0.25 sorbate mg/mL + 20 Met 0.25 mg/mL + Tyr 0.25 mg/mL Cys 1 2 x
0.25 -- -- WN mg/mL 20 x 0.025 -- -- WN Tyr 0.74 2 x 0.25 -- --
Sharp mg/mL PA whole abdomen 20 x 0.025 -- -- WN Trp 1 2 x 0.25 --
.dagger. mg/mL 20 x 0.025 -- -- WN -- 2 x 0.25 -- -- WN 20 x 0.025
-- -- WN
[0262] Tyrosine and tryptophan were found to have a protective
effect against BoNT/A degradation. Tryptophan was found to have the
strongest protective effect. Cysteine, as well as the mixture
containing all 4 amino acids did not have a protective effect.
[0263] 2. Preparation of a Stable Liquid Botulinum Toxin B
Formulation
[0264] Liquid botulinum toxin preparations containing 350 ng/mL of
highly purified BoNT/B, 15% v/v polysorbate 20, an amino acid
selected from tyrosine (Tyr), tryptophan (Trp) and cysteine (Cys)
or a mixture of methionine (Met), tyrosine (Tyr), tryptophan (Trp)
and cysteine (Cys), and Phosphate Buffer Saline (PBS) at pH 7.4
were prepared, filtered using 0.22 .mu.m filters and stored in
siliconized 2 mL glass syringes for two weeks at 40.degree. C.,
after which a potency test was performed for each preparation as
described above.
[0265] The results are shown in table 2.
TABLE-US-00003 TABLE 2 an accelerated storage test (two weeks at
40.degree. C.) of amino acid additions on BoNT/B stability.
Paralysis results in mice: - = not analysed, WN = without note, PA
= paralysis and .dagger. = death. Potency test Formulation Dilution
in Inj. Potency rating BoNT/ 0.9 NaCl Dose Day Day B Amino with 3%
Buffer cone. acid HSA (times) (ng) 1 2 Day 3 PBS 350 Trp 0.25 10 x
1.75 -- -- PA pH 7.4 ng/mL mg/mL + 15% Cys 0.25 poly- mg/mL +
sorbate Met 0.25 20 mg/mL + Tyr 0.25 mg/mL Cys 1 mg/mL 10 x 1.75 --
-- PA Tyr 0.575 10 x 1.75 -- .dagger. mg/mL 10 x 1.75 -- .dagger.
Trp 1 35 x 0.5 -- -- PA mg/mL
[0266] Tyrosine and tryptophan were found to have a protective
effect against BoNT/B degradation. Cysteine, as well as the mixture
containing all 4 amino acids also had a protective effect but to a
weaker extent.
[0267] 3. Evaluation of Different Concentrations of Tryptophan and
Polysorbate 20
[0268] Liquid botulinum toxin preparations containing highly
purified BoNT/A or BoNT/B and various concentrations of polysorbate
20 (PS 20) and tryptophan and Phosphate Buffer Saline (PBS) at pH
7.4 were prepared, filtered using 0.22 .mu.m filters and stored in
siliconized 2 mL glass syringes. Hind limb paralysis potency tests
were performed for each preparation as described above.
[0269] The results are shown in table 3.
TABLE-US-00004 TABLE 3 evaluation of Trp and polysorbate 20 (PS20)
concentrations on BoNT/A or BoNT/B stability. Paralysis results in
mice: - =not analysed, W N = without note, PA = paralysis and
.dagger. = death. POTENCY TESTING Dilution Potency rating (1-3 d)
for samples stored Formulation in 0.9 at different temperatures and
lengths BoNT Trp NaCl with Inj. 5.degree. C. 25.degree. C. cone.
(mg/ PS20 3% HSA Dose 6 months 5 weeks 4 months BoNT (ng/mL) mL)
(%) (times) (ng) 1 d 2 d 3 d 1 d 2 d 3 d 1 d 2 d 3 d BoNT/ 15 8 15
1 x 0.75 -- .dagger. -- -- .dagger. -- -- PA A 5 x 0.15 -- --
.dagger. -- -- .dagger. -- -- WN 15 8 0.25 1 x 0.75 -- .dagger. --
-- .dagger.* -- -- .dagger. 5 x 0.15 -- -- .dagger. -- .dagger.* --
-- W N.sup.2 15 1 15 1 x 0.75 -- .dagger. -- .dagger. .dagger. 5 x
0.15 -- -- .dagger. -- -- .dagger. -- .dagger. PA.sup.3 BoNT/ 100 8
15 1 x 5 -- -- .dagger. -- -- .dagger. -- -- PA B 10 x 0.5 -- --
PA.sup.1 -- -- PA -- -- PA 100 8 0.25 1 x 5 -- -- .dagger. -- --
.dagger. .dagger. 10 x 0.5 -- -- PA.sup.4 -- -- W N.sup.1 -- -- PA
100 1 15 1 x 5 -- -- .dagger. -- -- .dagger. .dagger. 10 x 0.5 --
-- PA.sup.4 -- PA -- -- PA Paraysis degree (PA): 1. Toes affected;
2. Slightly numb in hind eg; 3. Both hind legs paralysed; 4. Hind
leg paralysed; Elution buffer from purification (5): 50 m M sodium
acetate pH 4.5 with 0.2% (v:v) polysorbate 20 and 400 mM sodium
chloride. * a mix up of two BoNT/A dilutions of the 25 .degree.C.
8mg/mL Trp 0.25 % polysorbate 20 has probably occurred.
[0270] 4. Evaluation of Different Salt Concentrations in BoNT/B
Preparations
[0271] Liquid botulinum toxin preparations containing 100 ng/mL of
highly purified BoNT/B, polysorbate 20, tryptophan from various
amino acid suppliers and a buffer selected from PBS pH 7.4 (Cal
biochem), 12 nM phosphate buffer pH 7 (Apoteket) and 20 mM sodium
acetate (NaAc) pH 5.5 (NaAc from Fluka and acetic acid from Merck)
were prepared, filtered using 0.22 .mu.m filters and stored in
siliconized 2 mL glass syringes. Hind limb paralysis potency tests
were performed for each preparation as described above.
[0272] The results are shown in table 4.
TABLE-US-00005 TABLE 4 evaluation of different salt concentrations
on stability of BoNT/B. Paralysis results in mice: - = not
analysed, W N = without note, PA = paralysis and .dagger. = death.
Potency testing Potency rating (1-3d) Dilution for samples stored
in 0.9 at different length BoNT/B Trp NaCI with Inj. 40.degree. C.
conc. manufacturer PS20 3% HSA Dose 2 weeks 5 weeks (ng/mL) Buffer
and conc. (%) (times) (ng) 1 d 2 d 3 d 1 d 2 d 3 d 100 PBS
Ajinomoto 15 1 x 5 -- .dagger. pH 7.4 4 mg/mL 10 x 0.5 -- -- PA 100
PBS Sigma 15 1 x 5 -- .dagger. pH 7.4 Aldrich 10 x 0.5 -- -- PA 4
mg/mL 100 PBS Sigma 15 1 x 5 -- .dagger. pH 7.4 Aldrich 10 x 0.5 --
-- PA 1 mg/mL 100 PBS Sigma 0.25 1 x 5 -- .dagger. -- .dagger. pH
7.4 Aldrich 10 x 0.5 -- -- PA -- -- PA.sup.2 4 mg/mL 100 12 mM
Sigma 15 1 x 5 -- -- WN Phosphate Aldrich 10 x 0.5 -- -- WN.sup.1
pH 7 4 mg/mL 100 20 mM Sigma 15 1 x 5 -- -- PA NaAc Aldrich 10 x
0.5 -- -- PA pH 5.5 4 mg/mL 1. Some loss of function: 2. Weak
paralysis
[0273] The results show that the preparations containing the PBS
buffer (containing sodium, chloride, phosphate and potassium ions)
appears to play a role in the stability of the botulinum toxin.
[0274] 5. Evaluation of Different Stabilizers
[0275] Liquid botulinum toxin preparations containing 15 ng/mL of
highly purified BoNT/A, a polysorbate 20 (PS20) or polysorbate 80
(PS80) or HSA, tryptophan and PBS were prepared, filtered using
0.22 .mu.m filters and stored in siliconized 2 mL glass syringes.
Hind limb paralysis potency tests were performed for each
preparation as described above.
[0276] The results are shown in table 5.
TABLE-US-00006 TABLE 5 evaluation of different surfactants on
stability of BoNT/A. Paralysis results in mice: - = not analysed, W
N = without note, PA = paralysis and .dagger. = death. Potency
testing Potency rating (1-3 d) for samples Dilution in stored at
different length BoNT/A 0.9 NaCl with Inj. 40.degree. C. conc. 3%
HSA Dose 6 days 4 weeks 3 months (ng/mL) Buffer Trp Stabiliser
(times) (ng) 1 d 2 d 3 d 1 d 2 d 3 d 1 d 2 d 3 d 15 PBS 1 mg/ PS 80
1.7 x 0.45 .dagger. .dagger. -- -- PA.sup.3 pH 7.4 mL 0.25% 15 x
0.05 .dagger. .dagger. -- -- WA 15 PBS 1 mg/ PS 20 1.7 x 0.45
.dagger. .dagger. -- -- PA.sup.2 pH 7.4 mL 0.25% 15 x 0.05 .dagger.
-- -- PA -- -- WN 15 PBS -- HSA 1.7 x 0.45 .dagger. .dagger. --
.dagger. pH 7.4 1 mg/mL 15 x 0.05 .dagger. .dagger. -- -- PA.sup.1
1. Severe paralysis both hind legs; 2. Angles paws; 3. Severe
paralysis
[0277] 6. Evaluation of Different Formulations
[0278] Liquid botulinum toxin preparations containing 10 ng/mL of
highly purified BoNT/A, 0.25% PS80, 1 mg/mL tryptophan and PBS were
prepared as described above. The pH was adjusted to 6.6 and 7.0 by
adding HCl. Each preparation was stored 5 weeks at 40.degree.
C.
[0279] Each preparation was then diluted 10 times and hind limb
paralysis potency tests were performed as described above (0.05 ng
per injection). In both cases, hind limb paralysis was observed at
day 3. The paralysis was stronger with the pH 6.6 preparation.
[0280] 7. Evaluation of Different Formulations
[0281] Liquid botulinum toxin preparations containing 0.3 ng/mL of
highly purified BoNT/A, a polysorbate selected from PS20 and PS80,
1 mg/mL tryptophan and 12 mM PBS at pH 7.4 were prepared as
described above. The pH of each preparation was adjusted to pH 6.6
or 6.9 by adding 1.2 M HCl.
[0282] Polysorbate 20 was tested at one concentration, 0.2% w/v,
corresponding to about 20 times its CMC (critical micellar
concentration, about 0.01% w/v at 21.degree. C.). Polysorbate 80
was tested 0.04% and 0.2% w/v, corresponding respectively to about
20 and 100 times its CMC (about 0.002% w/v at 21.degree. C.).
TABLE-US-00007 TABLE 6 Choice of polysorbate and pH Composition
PS20 % w/v PS20 % w/v pH PS20-1 0.2 -- 6.6 PS20-2 0.2 -- 6.9 PS80-1
-- 0.04 6.6 PS80-2 -- 0.04 6.9 PS80-3 -- 0.2 6.6
[0283] For each preparation, a volume of 0.5 mL was filled in 1 mL
long glass syringes (BD) and sealed with a fluorocarbon coated
plunger.
[0284] The potency was measured by hind limb paralysis test on mice
as described above.
[0285] No decrease in potency was observed in any formulation after
6 months storage at 5.degree. C. and after 25.degree. C.
[0286] 8. Evaluation of Different Formulations
[0287] Nineteen different formulations containing highly purified
botulinum neurotoxin type A were prepared with varying
concentrations of polysorbate 80, tryptophan, sodium phosphate,
sodium chloride, potassium chloride and varying pH. Each
formulation had a target nominal potency of 500 U/mL. Each
formulation was degassed, filtered through 0.2 .mu.m filter and
filled into vials. Nitrogen gas was used as a protective atmosphere
in the vials. The filling was performed in an anaerobic chamber.
Each formulation was filled in 1 mL aliquots in a nitrogen
atmosphere in 2 mL glass vials capped with FluroTec.RTM. stoppers
sealed with aluminium flip off seals and stored upright.
[0288] The stability of the 19 formulations was assessed at
5.degree. C., 25.degree. C. and 37.degree. C. using BoTest to
measure potency.
TABLE-US-00008 TABLE 7 Excipient compositions Sodium Exp phosphate
Tryptophan Polysorbate NaCl KCl Name PH (mM) (mg/mL) 80 (v %) (mM)
(mM) N1 6.3 2 0.25 0.01 25 0 N2 7.2 2 0.25 0.01 255 0 N3 6.3 50
0.25 0.01 255 10 N4 7.2 50 0.25 0.01 25 10 N5 6.3 2 3 0.01 255 10
N6 7.2 2 3 0.01 25 10 N7 6.3 50 3 0.01 25 0 N8 7.2 50 3 0.01 255 0
N9 6.3 2 0.25 1 25 10 N10 7.2 2 0.25 1 255 10 N11 6.3 50 0.25 1 255
0 N12 7.2 50 0.25 1 25 0 N13 6.3 2 3 1 255 0 N14 7.2 2 3 1 25 0 N15
6.3 50 3 1 25 10 N16 7.2 50 3 1 255 10 N17 6.75 10 1.625 0.1 140
3
TABLE-US-00009 TABLE 8 Packaging components Article number, Article
Supplier Clear glass vial of boro silicate 1097221, Schott Type I
plus, 2 mL Grey Flurotec coated bromobutyl 1356 4023/50, West
stopper Westar RS, 13 mm Aluminium flip off seals, 13 mm 5920-6623,
West
[0289] For all formulations the solution remained clear and for
most parts colourless.
[0290] The excipients concentrations tested in this study seem not
to affect the pH of the formulations during the time interval
tested. The potency results are presented in table 9.
TABLE-US-00010 TABLE 9 Botest potency results Remaining potency
Baseline compared to base line potency (BoTest) (U/mL) 2 month's 6
month's 6 months (Botest) 37.degree. C. 25.degree. C. 5.degree. C.
pH 0 month U/mL % U/mL % U/mL % N1 6.3 86 0 0 0 0 39 45 N2 7.2 474
210 44 389 82 485 102 N3 6.3 449 288 64 406 90 512 114 N4 7.2 299
62 21 368 123 406 136 N5 6.3 378 263 70 385 102 422 112 N6 7.2 93 0
0 0 0 52 56 N7 6.3 238 0 0 0 0 239 100 N8 7.2 375 305 81 402 107
450 120 N9 6.3 196 0 0 100 51 294 150 N10 7.2 354 201 57 408 115
411 116 N11 6.3 438 197 45 372 85 492 112 N12 7.2 411 96 23 295 72
417 101 N13 6.3 304 185 61 403 133 416 137 N14 7.2 206 0 0 0 0 183
89 N15 6.3 197 155 79 231 117 214 109 N16 7.2 476 227 48 390 82 685
144 N17 6.75 402 250 62 286 71 488 121
[0291] For several compositions there was no more than 30% loss in
potency over 6 months at 5.degree. C. and/or no more than about 40%
loss in potency over 3 months at 25.degree. C. and/or no more than
about 50% loss in potency over 2 months at 37.degree. C.
[0292] 9. Evaluation of PS 60
[0293] A formulation containing highly purified botulinum
neurotoxin type A was prepared with 0.1% (v/v) PS60, 1 mg/mL
L-Tryptophan, 10 mM sodium phosphate, 140 mM sodium chloride, 3 mM
potassium chloride and water for injection. The pH was adjusted to
6.75 with HCl. The formulation had a target nominal potency of 100
U/mL. The formulation was degassed, filtered through 0.2 .mu.m
filters and filled into 2 mL vials aseptically in an anaerobic
chamber with nitrogen atmosphere with a fill volume of 1 mL.
Nitrogen gas was used as protective atmosphere in the vials. The
vials were capped with FluroTec.RTM. stoppers sealed with aluminium
flip off seals.
TABLE-US-00011 TABLE 10 Packaging components Article number,
Article Supplier Clear glass vial of boro silicate 1097221, Schott
Type I plus, 2 mL 13 mm Inj stopper coated bromobutyl INJ13TB3WRS,
4023-50 grey Nordic Pack Blue aluminium flip off seals, 13 mm
5920-1164, Nordic Pack
[0294] The potency over time at 37.degree. C. and 25.degree. C. was
measured by the MLD50 test as described herein.
[0295] At 37.degree. C., the remaining potency after 9 weeks was
around 50-55% of the initial potency.
[0296] At 25.degree. C., the remaining potency after 3 months was
about 80% of the initial potency.
Sequence CWU 1
1
711296PRTClostridium botulinum 1Met Pro Phe Val Asn Lys Gln Phe Asn
Tyr Lys Asp Pro Val Asn Gly1 5 10 15Val Asp Ile Ala Tyr Ile Lys Ile
Pro Asn Ala Gly Gln Met Gln Pro 20 25 30Val Lys Ala Phe Lys Ile His
Asn Lys Ile Trp Val Ile Pro Glu Arg 35 40 45Asp Thr Phe Thr Asn Pro
Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60Ala Lys Gln Val Pro
Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr65 70 75 80Asp Asn Glu
Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95Arg Ile
Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val 100 105
110Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys
115 120 125Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
Ser Tyr 130 135 140Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro
Ser Ala Asp Ile145 150 155 160Ile Gln Phe Glu Cys Lys Ser Phe Gly
His Glu Val Leu Asn Leu Thr 165 170 175Arg Asn Gly Tyr Gly Ser Thr
Gln Tyr Ile Arg Phe Ser Pro Asp Phe 180 185 190Thr Phe Gly Phe Glu
Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205Gly Ala Gly
Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220Leu
Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn225 230
235 240Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly
Leu 245 250 255Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His
Asp Ala Lys 260 265 270Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg
Leu Tyr Tyr Tyr Asn 275 280 285Lys Phe Lys Asp Ile Ala Ser Thr Leu
Asn Lys Ala Lys Ser Ile Val 290 295 300Gly Thr Thr Ala Ser Leu Gln
Tyr Met Lys Asn Val Phe Lys Glu Lys305 310 315 320Tyr Leu Leu Ser
Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335Lys Phe
Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp 340 345
350Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn
355 360 365Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
Asn Tyr 370 375 380Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn
Leu Ala Ala Asn385 390 395 400Phe Asn Gly Gln Asn Thr Glu Ile Asn
Asn Met Asn Phe Thr Lys Leu 405 410 415Lys Asn Phe Thr Gly Leu Phe
Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430Gly Ile Ile Thr Ser
Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445Ala Leu Asn
Asp Leu Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe 450 455 460Ser
Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu465 470
475 480Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser
Leu 485 490 495Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp
Asn Glu Pro 500 505 510Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp
Ile Ile Gly Gln Leu 515 520 525Glu Leu Met Pro Asn Ile Glu Arg Phe
Pro Asn Gly Lys Lys Tyr Glu 530 535 540Leu Asp Lys Tyr Thr Met Phe
His Tyr Leu Arg Ala Gln Glu Phe Glu545 550 555 560His Gly Lys Ser
Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu 565 570 575Leu Asn
Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys 580 585
590Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu
595 600 605Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser
Thr Thr 610 615 620Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr
Ile Gly Pro Ala625 630 635 640Leu Asn Ile Gly Asn Met Leu Tyr Lys
Asp Asp Phe Val Gly Ala Leu 645 650 655Ile Phe Ser Gly Ala Val Ile
Leu Leu Glu Phe Ile Pro Glu Ile Ala 660 665 670Ile Pro Val Leu Gly
Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys 675 680 685Val Leu Thr
Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu 690 695 700Lys
Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys705 710
715 720Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala
Leu 725 730 735Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr
Gln Tyr Asn 740 745 750Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn
Phe Asn Ile Asp Asp 755 760 765Leu Ser Ser Lys Leu Asn Glu Ser Ile
Asn Lys Ala Met Ile Asn Ile 770 775 780Asn Lys Phe Leu Asn Gln Cys
Ser Val Ser Tyr Leu Met Asn Ser Met785 790 795 800Ile Pro Tyr Gly
Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys 805 810 815Asp Ala
Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly 820 825
830Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp
835 840 845Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu
Leu Ser 850 855 860Thr Phe Thr Glu Tyr Ile Lys Asn Ile Ile Asn Thr
Ser Ile Leu Asn865 870 875 880Leu Arg Tyr Glu Ser Asn His Leu Ile
Asp Leu Ser Arg Tyr Ala Ser 885 890 895Lys Ile Asn Ile Gly Ser Lys
Val Asn Phe Asp Pro Ile Asp Lys Asn 900 905 910Gln Ile Gln Leu Phe
Asn Leu Glu Ser Ser Lys Ile Glu Val Ile Leu 915 920 925Lys Asn Ala
Ile Val Tyr Asn Ser Met Tyr Glu Asn Phe Ser Thr Ser 930 935 940Phe
Trp Ile Arg Ile Pro Lys Tyr Phe Asn Ser Ile Ser Leu Asn Asn945 950
955 960Glu Tyr Thr Ile Ile Asn Cys Met Glu Asn Asn Ser Gly Trp Lys
Val 965 970 975Ser Leu Asn Tyr Gly Glu Ile Ile Trp Thr Leu Gln Asp
Thr Gln Glu 980 985 990Ile Lys Gln Arg Val Val Phe Lys Tyr Ser Gln
Met Ile Asn Ile Ser 995 1000 1005Asp Tyr Ile Asn Arg Trp Ile Phe
Val Thr Ile Thr Asn Asn Arg 1010 1015 1020Leu Asn Asn Ser Lys Ile
Tyr Ile Asn Gly Arg Leu Ile Asp Gln 1025 1030 1035Lys Pro Ile Ser
Asn Leu Gly Asn Ile His Ala Ser Asn Asn Ile 1040 1045 1050Met Phe
Lys Leu Asp Gly Cys Arg Asp Thr His Arg Tyr Ile Trp 1055 1060
1065Ile Lys Tyr Phe Asn Leu Phe Asp Lys Glu Leu Asn Glu Lys Glu
1070 1075 1080Ile Lys Asp Leu Tyr Asp Asn Gln Ser Asn Ser Gly Ile
Leu Lys 1085 1090 1095Asp Phe Trp Gly Asp Tyr Leu Gln Tyr Asp Lys
Pro Tyr Tyr Met 1100 1105 1110Leu Asn Leu Tyr Asp Pro Asn Lys Tyr
Val Asp Val Asn Asn Val 1115 1120 1125Gly Ile Arg Gly Tyr Met Tyr
Leu Lys Gly Pro Arg Gly Ser Val 1130 1135 1140Met Thr Thr Asn Ile
Tyr Leu Asn Ser Ser Leu Tyr Arg Gly Thr 1145 1150 1155Lys Phe Ile
Ile Lys Lys Tyr Ala Ser Gly Asn Lys Asp Asn Ile 1160 1165 1170Val
Arg Asn Asn Asp Arg Val Tyr Ile Asn Val Val Val Lys Asn 1175 1180
1185Lys Glu Tyr Arg Leu Ala Thr Asn Ala Ser Gln Ala Gly Val Glu
1190 1195 1200Lys Ile Leu Ser Ala Leu Glu Ile Pro Asp Val Gly Asn
Leu Ser 1205 1210 1215Gln Val Val Val Met Lys Ser Lys Asn Asp Gln
Gly Ile Thr Asn 1220 1225 1230Lys Cys Lys Met Asn Leu Gln Asp Asn
Asn Gly Asn Asp Ile Gly 1235 1240 1245Phe Ile Gly Phe His Gln Phe
Asn Asn Ile Ala Lys Leu Val Ala 1250 1255 1260Ser Asn Trp Tyr Asn
Arg Gln Ile Glu Arg Ser Ser Arg Thr Leu 1265 1270 1275Gly Cys Ser
Trp Glu Phe Ile Pro Val Asp Asp Gly Trp Gly Glu 1280 1285 1290Arg
Pro Leu 129521291PRTClostridium botulinum 2Met Pro Val Thr Ile Asn
Asn Phe Asn Tyr Asn Asp Pro Ile Asp Asn1 5 10 15Asn Asn Ile Ile Met
Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg 20 25 30Tyr Tyr Lys Ala
Phe Lys Ile Thr Asp Arg Ile Trp Ile Ile Pro Glu 35 40 45Arg Tyr Thr
Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly 50 55 60Ile Phe
Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn65 70 75
80Thr Asn Asp Lys Lys Asn Ile Phe Leu Gln Thr Met Ile Lys Leu Phe
85 90 95Asn Arg Ile Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met
Ile 100 105 110Ile Asn Gly Ile Pro Tyr Leu Gly Asp Arg Arg Val Pro
Leu Glu Glu 115 120 125Phe Asn Thr Asn Ile Ala Ser Val Thr Val Asn
Lys Leu Ile Ser Asn 130 135 140Pro Gly Glu Val Glu Arg Lys Lys Gly
Ile Phe Ala Asn Leu Ile Ile145 150 155 160Phe Gly Pro Gly Pro Val
Leu Asn Glu Asn Glu Thr Ile Asp Ile Gly 165 170 175Ile Gln Asn His
Phe Ala Ser Arg Glu Gly Phe Gly Gly Ile Met Gln 180 185 190Met Lys
Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gln Glu 195 200
205Asn Lys Gly Ala Ser Ile Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro
210 215 220Ala Leu Ile Leu Met His Glu Leu Ile His Val Leu His Gly
Leu Tyr225 230 235 240Gly Ile Lys Val Asp Asp Leu Pro Ile Val Pro
Asn Glu Lys Lys Phe 245 250 255Phe Met Gln Ser Thr Asp Ala Ile Gln
Ala Glu Glu Leu Tyr Thr Phe 260 265 270Gly Gly Gln Asp Pro Ser Ile
Ile Thr Pro Ser Thr Asp Lys Ser Ile 275 280 285Tyr Asp Lys Val Leu
Gln Asn Phe Arg Gly Ile Val Asp Arg Leu Asn 290 295 300Lys Val Leu
Val Cys Ile Ser Asp Pro Asn Ile Asn Ile Asn Ile Tyr305 310 315
320Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly
325 330 335Lys Tyr Ser Ile Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys
Ser Leu 340 345 350Met Phe Gly Phe Thr Glu Thr Asn Ile Ala Glu Asn
Tyr Lys Ile Lys 355 360 365Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu
Pro Pro Val Lys Ile Lys 370 375 380Asn Leu Leu Asp Asn Glu Ile Tyr
Thr Ile Glu Glu Gly Phe Asn Ile385 390 395 400Ser Asp Lys Asp Met
Glu Lys Glu Tyr Arg Gly Gln Asn Lys Ala Ile 405 410 415Asn Lys Gln
Ala Tyr Glu Glu Ile Ser Lys Glu His Leu Ala Val Tyr 420 425 430Lys
Ile Gln Met Cys Lys Ser Val Lys Ala Pro Gly Ile Cys Ile Asp 435 440
445Val Asp Asn Glu Asp Leu Phe Phe Ile Ala Asp Lys Asn Ser Phe Ser
450 455 460Asp Asp Leu Ser Lys Asn Glu Arg Ile Glu Tyr Asn Thr Gln
Ser Asn465 470 475 480Tyr Ile Glu Asn Asp Phe Pro Ile Asn Glu Leu
Ile Leu Asp Thr Asp 485 490 495Leu Ile Ser Lys Ile Glu Leu Pro Ser
Glu Asn Thr Glu Ser Leu Thr 500 505 510Asp Phe Asn Val Asp Val Pro
Val Tyr Glu Lys Gln Pro Ala Ile Lys 515 520 525Lys Ile Phe Thr Asp
Glu Asn Thr Ile Phe Gln Tyr Leu Tyr Ser Gln 530 535 540Thr Phe Pro
Leu Asp Ile Arg Asp Ile Ser Leu Thr Ser Ser Phe Asp545 550 555
560Asp Ala Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp
565 570 575Tyr Ile Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe
Ala Gly 580 585 590Trp Val Lys Gln Ile Val Asn Asp Phe Val Ile Glu
Ala Asn Lys Ser 595 600 605Asn Thr Met Asp Lys Ile Ala Asp Ile Ser
Leu Ile Val Pro Tyr Ile 610 615 620Gly Leu Ala Leu Asn Val Gly Asn
Glu Thr Ala Lys Gly Asn Phe Glu625 630 635 640Asn Ala Phe Glu Ile
Ala Gly Ala Ser Ile Leu Leu Glu Phe Ile Pro 645 650 655Glu Leu Leu
Ile Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr Ile 660 665 670Asp
Asn Lys Asn Lys Ile Ile Lys Thr Ile Asp Asn Ala Leu Thr Lys 675 680
685Arg Asn Glu Lys Trp Ser Asp Met Tyr Gly Leu Ile Val Ala Gln Trp
690 695 700Leu Ser Thr Val Asn Thr Gln Phe Tyr Thr Ile Lys Glu Gly
Met Tyr705 710 715 720Lys Ala Leu Asn Tyr Gln Ala Gln Ala Leu Glu
Glu Ile Ile Lys Tyr 725 730 735Arg Tyr Asn Ile Tyr Ser Glu Lys Glu
Lys Ser Asn Ile Asn Ile Asp 740 745 750Phe Asn Asp Ile Asn Ser Lys
Leu Asn Glu Gly Ile Asn Gln Ala Ile 755 760 765Asp Asn Ile Asn Asn
Phe Ile Asn Gly Cys Ser Val Ser Tyr Leu Met 770 775 780Lys Lys Met
Ile Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn785 790 795
800Thr Leu Lys Lys Asn Leu Leu Asn Tyr Ile Asp Glu Asn Lys Leu Tyr
805 810 815Leu Ile Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys
Tyr Leu 820 825 830Lys Thr Ile Met Pro Phe Asp Leu Ser Ile Tyr Thr
Asn Asp Thr Ile 835 840 845Leu Ile Glu Met Phe Asn Lys Tyr Asn Ser
Glu Ile Leu Asn Asn Ile 850 855 860Ile Leu Asn Leu Arg Tyr Lys Asp
Asn Asn Leu Ile Asp Leu Ser Gly865 870 875 880Tyr Gly Ala Lys Val
Glu Val Tyr Asp Gly Val Glu Leu Asn Asp Lys 885 890 895Asn Gln Phe
Lys Leu Thr Ser Ser Ala Asn Ser Lys Ile Arg Val Thr 900 905 910Gln
Asn Gln Asn Ile Ile Phe Asn Ser Val Phe Leu Asp Phe Ser Val 915 920
925Ser Phe Trp Ile Arg Ile Pro Lys Tyr Lys Asn Asp Gly Ile Gln Asn
930 935 940Tyr Ile His Asn Glu Tyr Thr Ile Ile Asn Cys Met Lys Asn
Asn Ser945 950 955 960Gly Trp Lys Ile Ser Ile Arg Gly Asn Arg Ile
Ile Trp Thr Leu Ile 965 970 975Asp Ile Asn Gly Lys Thr Lys Ser Val
Phe Phe Glu Tyr Asn Ile Arg 980 985 990Glu Asp Ile Ser Glu Tyr Ile
Asn Arg Trp Phe Phe Val Thr Ile Thr 995 1000 1005Asn Asn Leu Asn
Asn Ala Lys Ile Tyr Ile Asn Gly Lys Leu Glu 1010 1015 1020Ser Asn
Thr Asp Ile Lys Asp Ile Arg Glu Val Ile Ala Asn Gly 1025 1030
1035Glu Ile Ile Phe Lys Leu Asp Gly Asp Ile Asp Arg Thr Gln Phe
1040 1045 1050Ile Trp Met Lys Tyr Phe Ser Ile Phe Asn Thr Glu Leu
Ser Gln 1055 1060 1065Ser Asn Ile Glu Glu Arg Tyr Lys Ile Gln Ser
Tyr Ser Glu Tyr 1070 1075 1080Leu Lys Asp Phe Trp Gly Asn Pro Leu
Met Tyr Asn Lys Glu Tyr 1085 1090 1095Tyr Met Phe Asn Ala Gly Asn
Lys Asn Ser Tyr Ile Lys Leu Lys 1100 1105 1110Lys Asp Ser Pro Val
Gly Glu Ile Leu Thr Arg Ser Lys Tyr Asn 1115 1120 1125Gln Asn Ser
Lys Tyr Ile Asn Tyr Arg Asp Leu Tyr Ile Gly Glu 1130 1135 1140Lys
Phe Ile Ile Arg Arg Lys Ser Asn Ser Gln Ser Ile Asn Asp 1145 1150
1155Asp Ile Val Arg Lys Glu Asp Tyr Ile
Tyr Leu Asp Phe Phe Asn 1160 1165 1170Leu Asn Gln Glu Trp Arg Val
Tyr Thr Tyr Lys Tyr Phe Lys Lys 1175 1180 1185Glu Glu Glu Lys Leu
Phe Leu Ala Pro Ile Ser Asp Ser Asp Glu 1190 1195 1200Phe Tyr Asn
Thr Ile Gln Ile Lys Glu Tyr Asp Glu Gln Pro Thr 1205 1210 1215Tyr
Ser Cys Gln Leu Leu Phe Lys Lys Asp Glu Glu Ser Thr Asp 1220 1225
1230Glu Ile Gly Leu Ile Gly Ile His Arg Phe Tyr Glu Ser Gly Ile
1235 1240 1245Val Phe Glu Glu Tyr Lys Asp Tyr Phe Cys Ile Ser Lys
Trp Tyr 1250 1255 1260Leu Lys Glu Val Lys Arg Lys Pro Tyr Asn Leu
Lys Leu Gly Cys 1265 1270 1275Asn Trp Gln Phe Ile Pro Lys Asp Glu
Gly Trp Thr Glu 1280 1285 129031291PRTClostridium botulinum 3Met
Pro Ile Thr Ile Asn Asn Phe Asn Tyr Ser Asp Pro Val Asp Asn1 5 10
15Lys Asn Ile Leu Tyr Leu Asp Thr His Leu Asn Thr Leu Ala Asn Glu
20 25 30Pro Glu Lys Ala Phe Arg Ile Thr Gly Asn Ile Trp Val Ile Pro
Asp 35 40 45Arg Phe Ser Arg Asn Ser Asn Pro Asn Leu Asn Lys Pro Pro
Arg Val 50 55 60Thr Ser Pro Lys Ser Gly Tyr Tyr Asp Pro Asn Tyr Leu
Ser Thr Asp65 70 75 80Ser Asp Lys Asp Pro Phe Leu Lys Glu Ile Ile
Lys Leu Phe Lys Arg 85 90 95Ile Asn Ser Arg Glu Ile Gly Glu Glu Leu
Ile Tyr Arg Leu Ser Thr 100 105 110Asp Ile Pro Phe Pro Gly Asn Asn
Asn Thr Pro Ile Asn Thr Phe Asp 115 120 125Phe Asp Val Asp Phe Asn
Ser Val Asp Val Lys Thr Arg Gln Gly Asn 130 135 140Asn Trp Val Lys
Thr Gly Ser Ile Asn Pro Ser Val Ile Ile Thr Gly145 150 155 160Pro
Arg Glu Asn Ile Ile Asp Pro Glu Thr Ser Thr Phe Lys Leu Thr 165 170
175Asn Asn Thr Phe Ala Ala Gln Glu Gly Phe Gly Ala Leu Ser Ile Ile
180 185 190Ser Ile Ser Pro Arg Phe Met Leu Thr Tyr Ser Asn Ala Thr
Asn Asp 195 200 205Val Gly Glu Gly Arg Phe Ser Lys Ser Glu Phe Cys
Met Asp Pro Ile 210 215 220Leu Ile Leu Met His Glu Leu Asn His Ala
Met His Asn Leu Tyr Gly225 230 235 240Ile Ala Ile Pro Asn Asp Gln
Thr Ile Ser Ser Val Thr Ser Asn Ile 245 250 255Phe Tyr Ser Gln Tyr
Asn Val Lys Leu Glu Tyr Ala Glu Ile Tyr Ala 260 265 270Phe Gly Gly
Pro Thr Ile Asp Leu Ile Pro Lys Ser Ala Arg Lys Tyr 275 280 285Phe
Glu Glu Lys Ala Leu Asp Tyr Tyr Arg Ser Ile Ala Lys Arg Leu 290 295
300Asn Ser Ile Thr Thr Ala Asn Pro Ser Ser Phe Asn Lys Tyr Ile
Gly305 310 315 320Glu Tyr Lys Gln Lys Leu Ile Arg Lys Tyr Arg Phe
Val Val Glu Ser 325 330 335Ser Gly Glu Val Thr Val Asn Arg Asn Lys
Phe Val Glu Leu Tyr Asn 340 345 350Glu Leu Thr Gln Ile Phe Thr Glu
Phe Asn Tyr Ala Lys Ile Tyr Asn 355 360 365Val Gln Asn Arg Lys Ile
Tyr Leu Ser Asn Val Tyr Thr Pro Val Thr 370 375 380Ala Asn Ile Leu
Asp Asp Asn Val Tyr Asp Ile Gln Asn Gly Phe Asn385 390 395 400Ile
Pro Lys Ser Asn Leu Asn Val Leu Phe Met Gly Gln Asn Leu Ser 405 410
415Arg Asn Pro Ala Leu Arg Lys Val Asn Pro Glu Asn Met Leu Tyr Leu
420 425 430Phe Thr Lys Phe Cys His Lys Ala Ile Asp Gly Arg Ser Leu
Tyr Asn 435 440 445Lys Thr Leu Asp Cys Arg Glu Leu Leu Val Lys Asn
Thr Asp Leu Pro 450 455 460Phe Ile Gly Asp Ile Ser Asp Val Lys Thr
Asp Ile Phe Leu Arg Lys465 470 475 480Asp Ile Asn Glu Glu Thr Glu
Val Ile Tyr Tyr Pro Asp Asn Val Ser 485 490 495Val Asp Gln Val Ile
Leu Ser Lys Asn Thr Ser Glu His Gly Gln Leu 500 505 510Asp Leu Leu
Tyr Pro Ser Ile Asp Ser Glu Ser Glu Ile Leu Pro Gly 515 520 525Glu
Asn Gln Val Phe Tyr Asp Asn Arg Thr Gln Asn Val Asp Tyr Leu 530 535
540Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asp Asn Val
Glu545 550 555 560Asp Phe Thr Phe Thr Arg Ser Ile Glu Glu Ala Leu
Asp Asn Ser Ala 565 570 575Lys Val Tyr Thr Tyr Phe Pro Thr Leu Ala
Asn Lys Val Asn Ala Gly 580 585 590Val Gln Gly Gly Leu Phe Leu Met
Trp Ala Asn Asp Val Val Glu Asp 595 600 605Phe Thr Thr Asn Ile Leu
Arg Lys Asp Thr Leu Asp Lys Ile Ser Asp 610 615 620Val Ser Ala Ile
Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Ser Asn625 630 635 640Ser
Val Arg Arg Gly Asn Phe Thr Glu Ala Phe Ala Val Thr Gly Val 645 650
655Thr Ile Leu Leu Glu Ala Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly
660 665 670Ala Phe Val Ile Tyr Ser Lys Val Gln Glu Arg Asn Glu Ile
Ile Lys 675 680 685Thr Ile Asp Asn Cys Leu Glu Gln Arg Ile Lys Arg
Trp Lys Asp Ser 690 695 700Tyr Glu Trp Met Met Gly Thr Trp Leu Ser
Arg Ile Ile Thr Gln Phe705 710 715 720Asn Asn Ile Ser Tyr Gln Met
Tyr Asp Ser Leu Asn Tyr Gln Ala Gly 725 730 735Ala Ile Lys Ala Lys
Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser 740 745 750Asp Lys Glu
Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu 755 760 765Asp
Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg 770 775
780Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val
Ile785 790 795 800Asp Glu Leu Asn Glu Phe Asp Arg Asn Thr Lys Ala
Lys Leu Ile Asn 805 810 815Leu Ile Asp Ser His Asn Ile Ile Leu Val
Gly Glu Val Asp Lys Leu 820 825 830Lys Ala Lys Val Asn Asn Ser Phe
Gln Asn Thr Ile Pro Phe Asn Ile 835 840 845Phe Ser Tyr Thr Asn Asn
Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr 850 855 860Phe Asn Asn Ile
Asn Asp Ser Lys Ile Leu Ser Leu Gln Asn Arg Lys865 870 875 880Asn
Thr Leu Val Asp Thr Ser Gly Tyr Asn Ala Glu Val Ser Glu Glu 885 890
895Gly Asp Val Gln Leu Asn Pro Ile Phe Pro Phe Asp Phe Lys Leu Gly
900 905 910Ser Ser Gly Glu Asp Arg Gly Lys Val Ile Val Thr Gln Asn
Glu Asn 915 920 925Ile Val Tyr Asn Ser Met Tyr Glu Ser Phe Ser Ile
Ser Phe Trp Ile 930 935 940Arg Ile Asn Lys Trp Val Ser Asn Leu Pro
Gly Tyr Thr Ile Ile Asp945 950 955 960Ser Val Lys Asn Asn Ser Gly
Trp Ser Ile Gly Ile Ile Ser Asn Phe 965 970 975Leu Val Phe Thr Leu
Lys Gln Asn Glu Asp Ser Glu Gln Ser Ile Asn 980 985 990Phe Ser Tyr
Asp Ile Ser Asn Asn Ala Pro Gly Tyr Asn Lys Trp Phe 995 1000
1005Phe Val Thr Val Thr Asn Asn Met Met Gly Asn Met Lys Ile Tyr
1010 1015 1020Ile Asn Gly Lys Leu Ile Asp Thr Ile Lys Val Lys Glu
Leu Thr 1025 1030 1035Gly Ile Asn Phe Ser Lys Thr Ile Thr Phe Glu
Ile Asn Lys Ile 1040 1045 1050Pro Asp Thr Gly Leu Ile Thr Ser Asp
Ser Asp Asn Ile Asn Met 1055 1060 1065Trp Ile Arg Asp Phe Tyr Ile
Phe Ala Lys Glu Leu Asp Gly Lys 1070 1075 1080Asp Ile Asn Ile Leu
Phe Asn Ser Leu Gln Tyr Thr Asn Val Val 1085 1090 1095Lys Asp Tyr
Trp Gly Asn Asp Leu Arg Tyr Asn Lys Glu Tyr Tyr 1100 1105 1110Met
Val Asn Ile Asp Tyr Leu Asn Arg Tyr Met Tyr Ala Asn Ser 1115 1120
1125Arg Gln Ile Val Phe Asn Thr Arg Arg Asn Asn Asn Asp Phe Asn
1130 1135 1140Glu Gly Tyr Lys Ile Ile Ile Lys Arg Ile Arg Gly Asn
Thr Asn 1145 1150 1155Asp Thr Arg Val Arg Gly Gly Asp Ile Leu Tyr
Phe Asp Met Thr 1160 1165 1170Ile Asn Asn Lys Ala Tyr Asn Leu Phe
Met Lys Asn Glu Thr Met 1175 1180 1185Tyr Ala Asp Asn His Ser Thr
Glu Asp Ile Tyr Ala Ile Gly Leu 1190 1195 1200Arg Glu Gln Thr Lys
Asp Ile Asn Asp Asn Ile Ile Phe Gln Ile 1205 1210 1215Gln Pro Met
Asn Asn Thr Tyr Tyr Tyr Ala Ser Gln Ile Phe Lys 1220 1225 1230Ser
Asn Phe Asn Gly Glu Asn Ile Ser Gly Ile Cys Ser Ile Gly 1235 1240
1245Thr Tyr Arg Phe Arg Leu Gly Gly Asp Trp Tyr Arg His Asn Tyr
1250 1255 1260Leu Val Pro Thr Val Lys Gln Gly Asn Tyr Ala Ser Leu
Leu Glu 1265 1270 1275Ser Thr Ser Thr His Trp Gly Phe Val Pro Val
Ser Glu 1280 1285 129041276PRTClostridium botulinum 4Met Thr Trp
Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp1 5 10 15Asn Asp
Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr 20 25 30Pro
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu 35 40
45Arg Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro
50 55 60Thr Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr
Asp65 70 75 80Glu Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu
Phe Lys Arg 85 90 95Ile Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn
Tyr Leu Val Val 100 105 110Gly Ser Pro Phe Met Gly Asp Ser Ser Thr
Pro Glu Asp Thr Phe Asp 115 120 125Phe Thr Arg His Thr Thr Asn Ile
Ala Val Glu Lys Phe Glu Asn Gly 130 135 140Ser Trp Lys Val Thr Asn
Ile Ile Thr Pro Ser Val Leu Ile Phe Gly145 150 155 160Pro Leu Pro
Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly 165 170 175Gln
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu 180 185
190Lys Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn
195 200 205Gln Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp
Pro Val 210 215 220Ile Ala Leu Met His Glu Leu Thr His Ser Leu His
Gln Leu Tyr Gly225 230 235 240Ile Asn Ile Pro Ser Asp Lys Arg Ile
Arg Pro Gln Val Ser Glu Gly 245 250 255Phe Phe Ser Gln Asp Gly Pro
Asn Val Gln Phe Glu Glu Leu Tyr Thr 260 265 270Phe Gly Gly Leu Asp
Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln 275 280 285Leu Arg Glu
Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu 290 295 300Asn
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp305 310
315 320Lys Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp
Asn 325 330 335Thr Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser
Leu Tyr Ser 340 345 350Asp Leu Thr Asn Val Met Ser Glu Val Val Tyr
Ser Ser Gln Tyr Asn 355 360 365Val Lys Asn Arg Thr His Tyr Phe Ser
Arg His Tyr Leu Pro Val Phe 370 375 380Ala Asn Ile Leu Asp Asp Asn
Ile Tyr Thr Ile Arg Asp Gly Phe Asn385 390 395 400Leu Thr Asn Lys
Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu 405 410 415Arg Asn
Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu 420 425
430Phe Thr Lys Val Cys Leu Arg Leu Thr Lys Asn Ser Arg Asp Asp Ser
435 440 445Thr Cys Ile Lys Val Lys Asn Asn Arg Leu Pro Tyr Val Ala
Asp Lys 450 455 460Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn Lys Ile
Ile Thr Asp Glu465 470 475 480Thr Asn Val Gln Asn Tyr Ser Asp Lys
Phe Ser Leu Asp Glu Ser Ile 485 490 495Leu Asp Gly Gln Val Pro Ile
Asn Pro Glu Ile Val Asp Pro Leu Leu 500 505 510Pro Asn Val Asn Met
Glu Pro Leu Asn Leu Pro Gly Glu Glu Ile Val 515 520 525Phe Tyr Asp
Asp Ile Thr Lys Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr 530 535 540Tyr
Leu Glu Ser Gln Lys Leu Ser Asn Asn Val Glu Asn Ile Thr Leu545 550
555 560Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr Ser Asn Lys Ile Tyr
Thr 565 570 575Phe Leu Pro Ser Leu Ala Glu Lys Val Asn Lys Gly Val
Gln Ala Gly 580 585 590Leu Phe Leu Asn Trp Ala Asn Glu Val Val Glu
Asp Phe Thr Thr Asn 595 600 605Ile Met Lys Lys Asp Thr Leu Asp Lys
Ile Ser Asp Val Ser Val Ile 610 615 620Ile Pro Tyr Ile Gly Pro Ala
Leu Asn Ile Gly Asn Ser Ala Leu Arg625 630 635 640Gly Asn Phe Asn
Gln Ala Phe Ala Thr Ala Gly Val Ala Phe Leu Leu 645 650 655Glu Gly
Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Val Phe Thr Phe 660 665
670Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile Ile Lys Thr Ile Glu Asn
675 680 685Cys Leu Glu Gln Arg Val Lys Arg Trp Lys Asp Ser Tyr Gln
Trp Met 690 695 700Val Ser Asn Trp Leu Ser Arg Ile Thr Thr Gln Phe
Asn His Ile Asn705 710 715 720Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
Gln Ala Asp Ala Ile Lys Ala 725 730 735Lys Ile Asp Leu Glu Tyr Lys
Lys Tyr Ser Gly Ser Asp Lys Glu Asn 740 745 750Ile Lys Ser Gln Val
Glu Asn Leu Lys Asn Ser Leu Asp Val Lys Ile 755 760 765Ser Glu Ala
Met Asn Asn Ile Asn Lys Phe Ile Arg Glu Cys Ser Val 770 775 780Thr
Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp Glu Leu Asn785 790
795 800Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu Ile Asn Leu Ile Asp
Ser 805 810 815His Asn Ile Ile Leu Val Gly Glu Val Asp Arg Leu Lys
Ala Lys Val 820 825 830Asn Glu Ser Phe Glu Asn Thr Met Pro Phe Asn
Ile Phe Ser Tyr Thr 835 840 845Asn Asn Ser Leu Leu Lys Asp Ile Ile
Asn Glu Tyr Phe Asn Ser Ile 850 855 860Asn Asp Ser Lys Ile Leu Ser
Leu Gln Asn Lys Lys Asn Ala Leu Val865 870 875 880Asp Thr Ser Gly
Tyr Asn Ala Glu Val Arg Val Gly Asp Asn Val Gln 885 890 895Leu Asn
Thr Ile Tyr Thr Asn Asp Phe Lys Leu Ser Ser Ser Gly Asp 900 905
910Lys Ile Ile Val Asn Leu Asn Asn Asn Ile Leu Tyr Ser Ala Ile Tyr
915 920 925Glu Asn Ser Ser Val Ser Phe Trp Ile Lys Ile Ser Lys Asp
Leu Thr 930 935 940Asn Ser His Asn Glu Tyr Thr Ile Ile Asn Ser Ile
Glu Gln Asn Ser945 950 955 960Gly Trp Lys Leu Cys Ile Arg Asn Gly
Asn Ile Glu Trp Ile Leu Gln 965 970 975Asp Val Asn Arg Lys Tyr Lys
Ser Leu Ile Phe Asp Tyr Ser Glu Ser 980 985 990Leu Ser His Thr Gly
Tyr Thr Asn Lys Trp Phe Phe Val Thr Ile Thr 995 1000 1005Asn Asn
Ile Met Gly Tyr Met Lys Leu Tyr Ile Asn Gly Glu Leu 1010 1015
1020Lys Gln Ser Gln Lys Ile Glu Asp Leu Asp Glu Val Lys Leu Asp
1025 1030
1035Lys Thr Ile Val Phe Gly Ile Asp Glu Asn Ile Asp Glu Asn Gln
1040 1045 1050Met Leu Trp Ile Arg Asp Phe Asn Ile Phe Ser Lys Glu
Leu Ser 1055 1060 1065Asn Glu Asp Ile Asn Ile Val Tyr Glu Gly Gln
Ile Leu Arg Asn 1070 1075 1080Val Ile Lys Asp Tyr Trp Gly Asn Pro
Leu Lys Phe Asp Thr Glu 1085 1090 1095Tyr Tyr Ile Ile Asn Asp Asn
Tyr Ile Asp Arg Tyr Ile Ala Pro 1100 1105 1110Glu Ser Asn Val Leu
Val Leu Val Gln Tyr Pro Asp Arg Ser Lys 1115 1120 1125Leu Tyr Thr
Gly Asn Pro Ile Thr Ile Lys Ser Val Ser Asp Lys 1130 1135 1140Asn
Pro Tyr Ser Arg Ile Leu Asn Gly Asp Asn Ile Ile Leu His 1145 1150
1155Met Leu Tyr Asn Ser Arg Lys Tyr Met Ile Ile Arg Asp Thr Asp
1160 1165 1170Thr Ile Tyr Ala Thr Gln Gly Gly Glu Cys Ser Gln Asn
Cys Val 1175 1180 1185Tyr Ala Leu Lys Leu Gln Ser Asn Leu Gly Asn
Tyr Gly Ile Gly 1190 1195 1200Ile Phe Ser Ile Lys Asn Ile Val Ser
Lys Asn Lys Tyr Cys Ser 1205 1210 1215Gln Ile Phe Ser Ser Phe Arg
Glu Asn Thr Met Leu Leu Ala Asp 1220 1225 1230Ile Tyr Lys Pro Trp
Arg Phe Ser Phe Lys Asn Ala Tyr Thr Pro 1235 1240 1245Val Ala Val
Thr Asn Tyr Glu Thr Lys Leu Leu Ser Thr Ser Ser 1250 1255 1260Phe
Trp Lys Phe Ile Ser Arg Asp Pro Gly Trp Val Glu 1265 1270
127551252PRTClostridium botulinum 5Met Pro Lys Ile Asn Ser Phe Asn
Tyr Asn Asp Pro Val Asn Asp Arg1 5 10 15Thr Ile Leu Tyr Ile Lys Pro
Gly Gly Cys Gln Glu Phe Tyr Lys Ser 20 25 30Phe Asn Ile Met Lys Asn
Ile Trp Ile Ile Pro Glu Arg Asn Val Ile 35 40 45Gly Thr Thr Pro Gln
Asp Phe His Pro Pro Thr Ser Leu Lys Asn Gly 50 55 60Asp Ser Ser Tyr
Tyr Asp Pro Asn Tyr Leu Gln Ser Asp Glu Glu Lys65 70 75 80Asp Arg
Phe Leu Lys Ile Val Thr Lys Ile Phe Asn Arg Ile Asn Asn 85 90 95Asn
Leu Ser Gly Gly Ile Leu Leu Glu Glu Leu Ser Lys Ala Asn Pro 100 105
110Tyr Leu Gly Asn Asp Asn Thr Pro Asp Asn Gln Phe His Ile Gly Asp
115 120 125Ala Ser Ala Val Glu Ile Lys Phe Ser Asn Gly Ser Gln Asp
Ile Leu 130 135 140Leu Pro Asn Val Ile Ile Met Gly Ala Glu Pro Asp
Leu Phe Glu Thr145 150 155 160Asn Ser Ser Asn Ile Ser Leu Arg Asn
Asn Tyr Met Pro Ser Asn His 165 170 175Gly Phe Gly Ser Ile Ala Ile
Val Thr Phe Ser Pro Glu Tyr Ser Phe 180 185 190Arg Phe Asn Asp Asn
Ser Met Asn Glu Phe Ile Gln Asp Pro Ala Leu 195 200 205Thr Leu Met
His Glu Leu Ile His Ser Leu His Gly Leu Tyr Gly Ala 210 215 220Lys
Gly Ile Thr Thr Lys Tyr Thr Ile Thr Gln Lys Gln Asn Pro Leu225 230
235 240Ile Thr Asn Ile Arg Gly Thr Asn Ile Glu Glu Phe Leu Thr Phe
Gly 245 250 255Gly Thr Asp Leu Asn Ile Ile Thr Ser Ala Gln Ser Asn
Asp Ile Tyr 260 265 270Thr Asn Leu Leu Ala Asp Tyr Lys Lys Ile Ala
Ser Lys Leu Ser Lys 275 280 285Val Gln Val Ser Asn Pro Leu Leu Asn
Pro Tyr Lys Asp Val Phe Glu 290 295 300Ala Lys Tyr Gly Leu Asp Lys
Asp Ala Ser Gly Ile Tyr Ser Val Asn305 310 315 320Ile Asn Lys Phe
Asn Asp Ile Phe Lys Lys Leu Tyr Ser Phe Thr Glu 325 330 335Phe Asp
Leu Ala Thr Lys Phe Gln Val Lys Cys Arg Gln Thr Tyr Ile 340 345
350Gly Gln Tyr Lys Tyr Phe Lys Leu Ser Asn Leu Leu Asn Asp Ser Ile
355 360 365Tyr Asn Ile Ser Glu Gly Tyr Asn Ile Asn Asn Leu Lys Val
Asn Phe 370 375 380Arg Gly Gln Asn Ala Asn Leu Asn Pro Arg Ile Ile
Thr Pro Ile Thr385 390 395 400Gly Arg Gly Leu Val Lys Lys Ile Ile
Arg Phe Cys Lys Asn Ile Val 405 410 415Ser Val Lys Gly Ile Arg Lys
Ser Ile Cys Ile Glu Ile Asn Asn Gly 420 425 430Glu Leu Phe Phe Val
Ala Ser Glu Asn Ser Tyr Asn Asp Asp Asn Ile 435 440 445Asn Thr Pro
Lys Glu Ile Asp Asp Thr Val Thr Ser Asn Asn Asn Tyr 450 455 460Glu
Asn Asp Leu Asp Gln Val Ile Leu Asn Phe Asn Ser Glu Ser Ala465 470
475 480Pro Gly Leu Ser Asp Glu Lys Leu Asn Leu Thr Ile Gln Asn Asp
Ala 485 490 495Tyr Ile Pro Lys Tyr Asp Ser Asn Gly Thr Ser Asp Ile
Glu Gln His 500 505 510Asp Val Asn Glu Leu Asn Val Phe Phe Tyr Leu
Asp Ala Gln Lys Val 515 520 525Pro Glu Gly Glu Asn Asn Val Asn Leu
Thr Ser Ser Ile Asp Thr Ala 530 535 540Leu Leu Glu Gln Pro Lys Ile
Tyr Thr Phe Phe Ser Ser Glu Phe Ile545 550 555 560Asn Asn Val Asn
Lys Pro Val Gln Ala Ala Leu Phe Val Ser Trp Ile 565 570 575Gln Gln
Val Leu Val Asp Phe Thr Thr Glu Ala Asn Gln Lys Ser Thr 580 585
590Val Asp Lys Ile Ala Asp Ile Ser Ile Val Val Pro Tyr Ile Gly Leu
595 600 605Ala Leu Asn Ile Gly Asn Glu Ala Gln Lys Gly Asn Phe Lys
Asp Ala 610 615 620Leu Glu Leu Leu Gly Ala Gly Ile Leu Leu Glu Phe
Glu Pro Glu Leu625 630 635 640Leu Ile Pro Thr Ile Leu Val Phe Thr
Ile Lys Ser Phe Leu Gly Ser 645 650 655Ser Asp Asn Lys Asn Lys Val
Ile Lys Ala Ile Asn Asn Ala Leu Lys 660 665 670Glu Arg Asp Glu Lys
Trp Lys Glu Val Tyr Ser Phe Ile Val Ser Asn 675 680 685Trp Met Thr
Lys Ile Asn Thr Gln Phe Asn Lys Arg Lys Glu Gln Met 690 695 700Tyr
Gln Ala Leu Gln Asn Gln Val Asn Ala Ile Lys Thr Ile Ile Glu705 710
715 720Ser Lys Tyr Asn Ser Tyr Thr Leu Glu Glu Lys Asn Glu Leu Thr
Asn 725 730 735Lys Tyr Asp Ile Lys Gln Ile Glu Asn Glu Leu Asn Gln
Lys Val Ser 740 745 750Ile Ala Met Asn Asn Ile Asp Arg Phe Leu Thr
Glu Ser Ser Ile Ser 755 760 765Tyr Leu Met Lys Leu Ile Asn Glu Val
Lys Ile Asn Lys Leu Arg Glu 770 775 780Tyr Asp Glu Asn Val Lys Thr
Tyr Leu Leu Asn Tyr Ile Ile Gln His785 790 795 800Gly Ser Ile Leu
Gly Glu Ser Gln Gln Glu Leu Asn Ser Met Val Thr 805 810 815Asp Thr
Leu Asn Asn Ser Ile Pro Phe Lys Leu Ser Ser Tyr Thr Asp 820 825
830Asp Lys Ile Leu Ile Ser Tyr Phe Asn Lys Phe Phe Lys Arg Ile Lys
835 840 845Ser Ser Ser Val Leu Asn Met Arg Tyr Lys Asn Asp Lys Tyr
Val Asp 850 855 860Thr Ser Gly Tyr Asp Ser Asn Ile Asn Ile Asn Gly
Asp Val Tyr Lys865 870 875 880Tyr Pro Thr Asn Lys Asn Gln Phe Gly
Ile Tyr Asn Asp Lys Leu Ser 885 890 895Glu Val Asn Ile Ser Gln Asn
Asp Tyr Ile Ile Tyr Asp Asn Lys Tyr 900 905 910Lys Asn Phe Ser Ile
Ser Phe Trp Val Arg Ile Pro Asn Tyr Asp Asn 915 920 925Lys Ile Val
Asn Val Asn Asn Glu Tyr Thr Ile Ile Asn Cys Met Arg 930 935 940Asp
Asn Asn Ser Gly Trp Lys Val Ser Leu Asn His Asn Glu Ile Ile945 950
955 960Trp Thr Leu Gln Asp Asn Ala Gly Ile Asn Gln Lys Leu Ala Phe
Asn 965 970 975Tyr Gly Asn Ala Asn Gly Ile Ser Asp Tyr Ile Asn Lys
Trp Ile Phe 980 985 990Val Thr Ile Thr Asn Asp Arg Leu Gly Asp Ser
Lys Leu Tyr Ile Asn 995 1000 1005Gly Asn Leu Ile Asp Gln Lys Ser
Ile Leu Asn Leu Gly Asn Ile 1010 1015 1020His Val Ser Asp Asn Ile
Leu Phe Lys Ile Val Asn Cys Ser Tyr 1025 1030 1035Thr Arg Tyr Ile
Gly Ile Arg Tyr Phe Asn Ile Phe Asp Lys Glu 1040 1045 1050Leu Asp
Glu Thr Glu Ile Gln Thr Leu Tyr Ser Asn Glu Pro Asn 1055 1060
1065Thr Asn Ile Leu Lys Asp Phe Trp Gly Asn Tyr Leu Leu Tyr Asp
1070 1075 1080Lys Glu Tyr Tyr Leu Leu Asn Val Leu Lys Pro Asn Asn
Phe Ile 1085 1090 1095Asp Arg Arg Lys Asp Ser Thr Leu Ser Ile Asn
Asn Ile Arg Ser 1100 1105 1110Thr Ile Leu Leu Ala Asn Arg Leu Tyr
Ser Gly Ile Lys Val Lys 1115 1120 1125Ile Gln Arg Val Asn Asn Ser
Ser Thr Asn Asp Asn Leu Val Arg 1130 1135 1140Lys Asn Asp Gln Val
Tyr Ile Asn Phe Val Ala Ser Lys Thr His 1145 1150 1155Leu Phe Pro
Leu Tyr Ala Asp Thr Ala Thr Thr Asn Lys Glu Lys 1160 1165 1170Thr
Ile Lys Ile Ser Ser Ser Gly Asn Arg Phe Asn Gln Val Val 1175 1180
1185Val Met Asn Ser Val Gly Asn Asn Cys Thr Met Asn Phe Lys Asn
1190 1195 1200Asn Asn Gly Asn Asn Ile Gly Leu Leu Gly Phe Lys Ala
Asp Thr 1205 1210 1215Val Val Ala Ser Thr Trp Tyr Tyr Thr His Met
Arg Asp His Thr 1220 1225 1230Asn Ser Asn Gly Cys Phe Trp Asn Phe
Ile Ser Glu Glu His Gly 1235 1240 1245Trp Gln Glu Lys
125061274PRTClostridium botulinum 6Met Pro Val Ala Ile Asn Ser Phe
Asn Tyr Asn Asp Pro Val Asn Asp1 5 10 15Asp Thr Ile Leu Tyr Met Gln
Ile Pro Tyr Glu Glu Lys Ser Lys Lys 20 25 30Tyr Tyr Lys Ala Phe Glu
Ile Met Arg Asn Val Trp Ile Ile Pro Glu 35 40 45Arg Asn Thr Ile Gly
Thr Asn Pro Ser Asp Phe Asp Pro Pro Ala Ser 50 55 60Leu Lys Asn Gly
Ser Ser Ala Tyr Tyr Asp Pro Asn Tyr Leu Thr Thr65 70 75 80Asp Ala
Glu Lys Asp Arg Tyr Leu Lys Thr Thr Ile Lys Leu Phe Lys 85 90 95Arg
Ile Asn Ser Asn Pro Ala Gly Lys Val Leu Leu Gln Glu Ile Ser 100 105
110Tyr Ala Lys Pro Tyr Leu Gly Asn Asp His Thr Pro Ile Asp Glu Phe
115 120 125Ser Pro Val Thr Arg Thr Thr Ser Val Asn Ile Lys Leu Ser
Thr Asn 130 135 140Val Glu Ser Ser Met Leu Leu Asn Leu Leu Val Leu
Gly Ala Gly Pro145 150 155 160Asp Ile Phe Glu Ser Cys Cys Tyr Pro
Val Arg Lys Leu Ile Asp Pro 165 170 175Asp Val Val Tyr Asp Pro Ser
Asn Tyr Gly Phe Gly Ser Ile Asn Ile 180 185 190Val Thr Phe Ser Pro
Glu Tyr Glu Tyr Thr Phe Asn Asp Ile Ser Gly 195 200 205Gly His Asn
Ser Ser Thr Glu Ser Phe Ile Ala Asp Pro Ala Ile Ser 210 215 220Leu
Ala His Glu Leu Ile His Ala Leu His Gly Leu Tyr Gly Ala Arg225 230
235 240Gly Val Thr Tyr Glu Glu Thr Ile Glu Val Lys Gln Ala Pro Leu
Met 245 250 255Ile Ala Glu Lys Pro Ile Arg Leu Glu Glu Phe Leu Thr
Phe Gly Gly 260 265 270Gln Asp Leu Asn Ile Ile Thr Ser Ala Met Lys
Glu Lys Ile Tyr Asn 275 280 285Asn Leu Leu Ala Asn Tyr Glu Lys Ile
Ala Thr Arg Leu Ser Glu Val 290 295 300Asn Ser Ala Pro Pro Glu Tyr
Asp Ile Asn Glu Tyr Lys Asp Tyr Phe305 310 315 320Gln Trp Lys Tyr
Gly Leu Asp Lys Asn Ala Asp Gly Ser Tyr Thr Val 325 330 335Asn Glu
Asn Lys Phe Asn Glu Ile Tyr Lys Lys Leu Tyr Ser Phe Thr 340 345
350Glu Ser Asp Leu Ala Asn Lys Phe Lys Val Lys Cys Arg Asn Thr Tyr
355 360 365Phe Ile Lys Tyr Glu Phe Leu Lys Val Pro Asn Leu Leu Asp
Asp Asp 370 375 380Ile Tyr Thr Val Ser Glu Gly Phe Asn Ile Gly Asn
Leu Ala Val Asn385 390 395 400Asn Arg Gly Gln Ser Ile Lys Leu Asn
Pro Lys Ile Ile Asp Ser Ile 405 410 415Pro Asp Lys Gly Leu Val Glu
Lys Ile Val Lys Phe Cys Lys Ser Val 420 425 430Ile Pro Arg Lys Gly
Thr Lys Ala Pro Pro Arg Leu Cys Ile Arg Val 435 440 445Asn Asn Ser
Glu Leu Phe Phe Val Ala Ser Glu Ser Ser Tyr Asn Glu 450 455 460Asn
Asp Ile Asn Thr Pro Lys Glu Ile Asp Asp Thr Thr Asn Leu Asn465 470
475 480Asn Asn Tyr Arg Asn Asn Leu Asp Glu Val Ile Leu Asp Tyr Asn
Ser 485 490 495Gln Thr Ile Pro Gln Ile Ser Asn Arg Thr Leu Asn Thr
Leu Val Gln 500 505 510Asp Asn Ser Tyr Val Pro Arg Tyr Asp Ser Asn
Gly Thr Ser Glu Ile 515 520 525Glu Glu Tyr Asp Val Val Asp Phe Asn
Val Phe Phe Tyr Leu His Ala 530 535 540Gln Lys Val Pro Glu Gly Glu
Thr Asn Ile Ser Leu Thr Ser Ser Ile545 550 555 560Asp Thr Ala Leu
Leu Glu Glu Ser Lys Asp Ile Phe Phe Ser Ser Glu 565 570 575Phe Ile
Asp Thr Ile Asn Lys Pro Val Asn Ala Ala Leu Phe Ile Asp 580 585
590Trp Ile Ser Lys Val Ile Arg Asp Phe Thr Thr Glu Ala Thr Gln Lys
595 600 605Ser Thr Val Asp Lys Ile Ala Asp Ile Ser Leu Ile Val Pro
Tyr Val 610 615 620Gly Leu Ala Leu Asn Ile Ile Ile Glu Ala Glu Lys
Gly Asn Phe Glu625 630 635 640Glu Ala Phe Glu Leu Leu Gly Val Gly
Ile Leu Leu Glu Phe Val Pro 645 650 655Glu Leu Thr Ile Pro Val Ile
Leu Val Phe Thr Ile Lys Ser Tyr Ile 660 665 670Asp Ser Tyr Glu Asn
Lys Asn Lys Ala Ile Lys Ala Ile Asn Asn Ser 675 680 685Leu Ile Glu
Arg Glu Ala Lys Trp Lys Glu Ile Tyr Ser Trp Ile Val 690 695 700Ser
Asn Trp Leu Thr Arg Ile Asn Thr Gln Phe Asn Lys Arg Lys Glu705 710
715 720Gln Met Tyr Gln Ala Leu Gln Asn Gln Val Asp Ala Ile Lys Thr
Ala 725 730 735Ile Glu Tyr Lys Tyr Asn Asn Tyr Thr Ser Asp Glu Lys
Asn Arg Leu 740 745 750Glu Ser Glu Tyr Asn Ile Asn Asn Ile Glu Glu
Glu Leu Asn Lys Lys 755 760 765Val Ser Leu Ala Met Lys Asn Ile Glu
Arg Phe Met Thr Glu Ser Ser 770 775 780Ile Ser Tyr Leu Met Lys Leu
Ile Asn Glu Ala Lys Val Gly Lys Leu785 790 795 800Lys Lys Tyr Asp
Asn His Val Lys Ser Asp Leu Leu Asn Tyr Ile Leu 805 810 815Asp His
Arg Ser Ile Leu Gly Glu Gln Thr Asn Glu Leu Ser Asp Leu 820 825
830Val Thr Ser Thr Leu Asn Ser Ser Ile Pro Phe Glu Leu Ser Ser Tyr
835 840 845Thr Asn Asp Lys Ile Leu Ile Ile Tyr Phe Asn Arg Leu Tyr
Lys Lys 850 855 860Ile Lys Asp Ser Ser Ile Leu Asp Met Arg Tyr Glu
Asn Asn Lys Phe865 870 875 880Ile Asp Ile Ser Gly Tyr Gly Ser Asn
Ile Ser Ile Asn Gly Asn Val 885 890 895Tyr Ile Tyr Ser Thr Asn Arg
Asn Gln Phe Gly Ile Tyr Asn Ser Arg 900 905 910Leu Ser Glu Val Asn
Ile Ala Gln Asn Asn Asp Ile Ile Tyr Asn Ser 915 920 925Arg Tyr Gln
Asn Phe Ser Ile Ser Phe Trp Val Arg Ile Pro Lys His 930 935 940Tyr
Lys Pro Met Asn His Asn Arg Glu Tyr Thr Ile Ile Asn Cys Met945 950
955 960Gly Asn
Asn Asn Ser Gly Trp Lys Ile Ser Leu Arg Thr Val Arg Asp 965 970
975Cys Glu Ile Ile Trp Thr Leu Gln Asp Thr Ser Gly Asn Lys Glu Asn
980 985 990Leu Ile Phe Arg Tyr Glu Glu Leu Asn Arg Ile Ser Asn Tyr
Ile Asn 995 1000 1005Lys Trp Ile Phe Val Thr Ile Thr Asn Asn Arg
Leu Gly Asn Ser 1010 1015 1020Arg Ile Tyr Ile Asn Gly Asn Leu Ile
Val Glu Lys Ser Ile Ser 1025 1030 1035Asn Leu Gly Asp Ile His Val
Ser Asp Asn Ile Leu Phe Lys Ile 1040 1045 1050Val Gly Cys Asp Asp
Glu Thr Tyr Val Gly Ile Arg Tyr Phe Lys 1055 1060 1065Val Phe Asn
Thr Glu Leu Asp Lys Thr Glu Ile Glu Thr Leu Tyr 1070 1075 1080Ser
Asn Glu Pro Asp Pro Ser Ile Leu Lys Asn Tyr Trp Gly Asn 1085 1090
1095Tyr Leu Leu Tyr Asn Lys Lys Tyr Tyr Leu Phe Asn Leu Leu Arg
1100 1105 1110Lys Asp Lys Tyr Ile Thr Leu Asn Ser Gly Ile Leu Asn
Ile Asn 1115 1120 1125Gln Gln Arg Gly Val Thr Glu Gly Ser Val Phe
Leu Asn Tyr Lys 1130 1135 1140Leu Tyr Glu Gly Val Glu Val Ile Ile
Arg Lys Asn Gly Pro Ile 1145 1150 1155Asp Ile Ser Asn Thr Asp Asn
Phe Val Arg Lys Asn Asp Leu Ala 1160 1165 1170Tyr Ile Asn Val Val
Asp Arg Gly Val Glu Tyr Arg Leu Tyr Ala 1175 1180 1185Asp Thr Lys
Ser Glu Lys Glu Lys Ile Ile Arg Thr Ser Asn Leu 1190 1195 1200Asn
Asp Ser Leu Gly Gln Ile Ile Val Met Asp Ser Ile Gly Asn 1205 1210
1215Asn Cys Thr Met Asn Phe Gln Asn Asn Asn Gly Ser Asn Ile Gly
1220 1225 1230Leu Leu Gly Phe His Ser Asn Asn Leu Val Ala Ser Ser
Trp Tyr 1235 1240 1245Tyr Asn Asn Ile Arg Arg Asn Thr Ser Ser Asn
Gly Cys Phe Trp 1250 1255 1260Ser Ser Ile Ser Lys Glu Asn Gly Trp
Lys Glu 1265 127071297PRTClostridium botulinum 7Met Pro Val Asn Ile
Lys Asn Phe Asn Tyr Asn Asp Pro Ile Asn Asn1 5 10 15Asp Asp Ile Ile
Met Met Glu Pro Phe Asn Asp Pro Gly Pro Gly Thr 20 25 30Tyr Tyr Lys
Ala Phe Arg Ile Ile Asp Arg Ile Trp Ile Val Pro Glu 35 40 45Arg Phe
Thr Tyr Gly Phe Gln Pro Asp Gln Phe Asn Ala Ser Thr Gly 50 55 60Val
Phe Ser Lys Asp Val Tyr Glu Tyr Tyr Asp Pro Thr Tyr Leu Lys65 70 75
80Thr Asp Ala Glu Lys Asp Lys Phe Leu Lys Thr Met Ile Lys Leu Phe
85 90 95Asn Arg Ile Asn Ser Lys Pro Ser Gly Gln Arg Leu Leu Asp Met
Ile 100 105 110Val Asp Ala Ile Pro Tyr Leu Gly Asn Ala Ser Thr Pro
Pro Asp Lys 115 120 125Phe Ala Ala Asn Val Ala Asn Val Ser Ile Asn
Lys Lys Ile Ile Gln 130 135 140Pro Gly Ala Glu Asp Gln Ile Lys Gly
Leu Met Thr Asn Leu Ile Ile145 150 155 160Phe Gly Pro Gly Pro Val
Leu Ser Asp Asn Phe Thr Asp Ser Met Ile 165 170 175Met Asn Gly His
Ser Pro Ile Ser Glu Gly Phe Gly Ala Arg Met Met 180 185 190Ile Arg
Phe Cys Pro Ser Cys Leu Asn Val Phe Asn Asn Val Gln Glu 195 200
205Asn Lys Asp Thr Ser Ile Phe Ser Arg Arg Ala Tyr Phe Ala Asp Pro
210 215 220Ala Leu Thr Leu Met His Glu Leu Ile His Val Leu His Gly
Leu Tyr225 230 235 240Gly Ile Lys Ile Ser Asn Leu Pro Ile Thr Pro
Asn Thr Lys Glu Phe 245 250 255Phe Met Gln His Ser Asp Pro Val Gln
Ala Glu Glu Leu Tyr Thr Phe 260 265 270Gly Gly His Asp Pro Ser Val
Ile Ser Pro Ser Thr Asp Met Asn Ile 275 280 285Tyr Asn Lys Ala Leu
Gln Asn Phe Gln Asp Ile Ala Asn Arg Leu Asn 290 295 300Ile Val Ser
Ser Ala Gln Gly Ser Gly Ile Asp Ile Ser Leu Tyr Lys305 310 315
320Gln Ile Tyr Lys Asn Lys Tyr Asp Phe Val Glu Asp Pro Asn Gly Lys
325 330 335Tyr Ser Val Asp Lys Asp Lys Phe Asp Lys Leu Tyr Lys Ala
Leu Met 340 345 350Phe Gly Phe Thr Glu Thr Asn Leu Ala Gly Glu Tyr
Gly Ile Lys Thr 355 360 365Arg Tyr Ser Tyr Phe Ser Glu Tyr Leu Pro
Pro Ile Lys Thr Glu Lys 370 375 380Leu Leu Asp Asn Thr Ile Tyr Thr
Gln Asn Glu Gly Phe Asn Ile Ala385 390 395 400Ser Lys Asn Leu Lys
Thr Glu Phe Asn Gly Gln Asn Lys Ala Val Asn 405 410 415Lys Glu Ala
Tyr Glu Glu Ile Ser Leu Glu His Leu Val Ile Tyr Arg 420 425 430Ile
Ala Met Cys Lys Pro Val Met Tyr Lys Asn Thr Gly Lys Ser Glu 435 440
445Gln Cys Ile Ile Val Asn Asn Glu Asp Leu Phe Phe Ile Ala Asn Lys
450 455 460Asp Ser Phe Ser Lys Asp Leu Ala Lys Ala Glu Thr Ile Ala
Tyr Asn465 470 475 480Thr Gln Asn Asn Thr Ile Glu Asn Asn Phe Ser
Ile Asp Gln Leu Ile 485 490 495Leu Asp Asn Asp Leu Ser Ser Gly Ile
Asp Leu Pro Asn Glu Asn Thr 500 505 510Glu Pro Phe Thr Asn Phe Asp
Asp Ile Asp Ile Pro Val Tyr Ile Lys 515 520 525Gln Ser Ala Leu Lys
Lys Ile Phe Val Asp Gly Asp Ser Leu Phe Glu 530 535 540Tyr Leu His
Ala Gln Thr Phe Pro Ser Asn Ile Glu Asn Leu Gln Leu545 550 555
560Thr Asn Ser Leu Asn Asp Ala Leu Arg Asn Asn Asn Lys Val Tyr Thr
565 570 575Phe Phe Ser Thr Asn Leu Val Glu Lys Ala Asn Thr Val Val
Gly Ala 580 585 590Ser Leu Phe Val Asn Trp Val Lys Gly Val Ile Asp
Asp Phe Thr Ser 595 600 605Glu Ser Thr Gln Lys Ser Thr Ile Asp Lys
Val Ser Asp Val Ser Ile 610 615 620Ile Ile Pro Tyr Ile Gly Pro Ala
Leu Asn Val Gly Asn Glu Thr Ala625 630 635 640Lys Glu Asn Phe Lys
Asn Ala Phe Glu Ile Gly Gly Ala Ala Ile Leu 645 650 655Met Glu Phe
Ile Pro Glu Leu Ile Val Pro Ile Val Gly Phe Phe Thr 660 665 670Leu
Glu Ser Tyr Val Gly Asn Lys Gly His Ile Ile Met Thr Ile Ser 675 680
685Asn Ala Leu Lys Lys Arg Asp Gln Lys Trp Thr Asp Met Tyr Gly Leu
690 695 700Ile Val Ser Gln Trp Leu Ser Thr Val Asn Thr Gln Phe Tyr
Thr Ile705 710 715 720Lys Glu Arg Met Tyr Asn Ala Leu Asn Asn Gln
Ser Gln Ala Ile Glu 725 730 735Lys Ile Ile Glu Asp Gln Tyr Asn Arg
Tyr Ser Glu Glu Asp Lys Met 740 745 750Asn Ile Asn Ile Asp Phe Asn
Asp Ile Asp Phe Lys Leu Asn Gln Ser 755 760 765Ile Asn Leu Ala Ile
Asn Asn Ile Asp Asp Phe Ile Asn Gln Cys Ser 770 775 780Ile Ser Tyr
Leu Met Asn Arg Met Ile Pro Leu Ala Val Lys Lys Leu785 790 795
800Lys Asp Phe Asp Asp Asn Leu Lys Arg Asp Leu Leu Glu Tyr Ile Asp
805 810 815Thr Asn Glu Leu Tyr Leu Leu Asp Glu Val Asn Ile Leu Lys
Ser Lys 820 825 830Val Asn Arg His Leu Lys Asp Ser Ile Pro Phe Asp
Leu Ser Leu Tyr 835 840 845Thr Lys Asp Thr Ile Leu Ile Gln Val Phe
Asn Asn Tyr Ile Ser Asn 850 855 860Ile Ser Ser Asn Ala Ile Leu Ser
Leu Ser Tyr Arg Gly Gly Arg Leu865 870 875 880Ile Asp Ser Ser Gly
Tyr Gly Ala Thr Met Asn Val Gly Ser Asp Val 885 890 895Ile Phe Asn
Asp Ile Gly Asn Gly Gln Phe Lys Leu Asn Asn Ser Glu 900 905 910Asn
Ser Asn Ile Thr Ala His Gln Ser Lys Phe Val Val Tyr Asp Ser 915 920
925Met Phe Asp Asn Phe Ser Ile Asn Phe Trp Val Arg Thr Pro Lys Tyr
930 935 940Asn Asn Asn Asp Ile Gln Thr Tyr Leu Gln Asn Glu Tyr Thr
Ile Ile945 950 955 960Ser Cys Ile Lys Asn Asp Ser Gly Trp Lys Val
Ser Ile Lys Gly Asn 965 970 975Arg Ile Ile Trp Thr Leu Ile Asp Val
Asn Ala Lys Ser Lys Ser Ile 980 985 990Phe Phe Glu Tyr Ser Ile Lys
Asp Asn Ile Ser Asp Tyr Ile Asn Lys 995 1000 1005Trp Phe Ser Ile
Thr Ile Thr Asn Asp Arg Leu Gly Asn Ala Asn 1010 1015 1020Ile Tyr
Ile Asn Gly Ser Leu Lys Lys Ser Glu Lys Ile Leu Asn 1025 1030
1035Leu Asp Arg Ile Asn Ser Ser Asn Asp Ile Asp Phe Lys Leu Ile
1040 1045 1050Asn Cys Thr Asp Thr Thr Lys Phe Val Trp Ile Lys Asp
Phe Asn 1055 1060 1065Ile Phe Gly Arg Glu Leu Asn Ala Thr Glu Val
Ser Ser Leu Tyr 1070 1075 1080Trp Ile Gln Ser Ser Thr Asn Thr Leu
Lys Asp Phe Trp Gly Asn 1085 1090 1095Pro Leu Arg Tyr Asp Thr Gln
Tyr Tyr Leu Phe Asn Gln Gly Met 1100 1105 1110Gln Asn Ile Tyr Ile
Lys Tyr Phe Ser Lys Ala Ser Met Gly Glu 1115 1120 1125Thr Ala Pro
Arg Thr Asn Phe Asn Asn Ala Ala Ile Asn Tyr Gln 1130 1135 1140Asn
Leu Tyr Leu Gly Leu Arg Phe Ile Ile Lys Lys Ala Ser Asn 1145 1150
1155Ser Arg Asn Ile Asn Asn Asp Asn Ile Val Arg Glu Gly Asp Tyr
1160 1165 1170Ile Tyr Leu Asn Ile Asp Asn Ile Ser Asp Glu Ser Tyr
Arg Val 1175 1180 1185Tyr Val Leu Val Asn Ser Lys Glu Ile Gln Thr
Gln Leu Phe Leu 1190 1195 1200Ala Pro Ile Asn Asp Asp Pro Thr Phe
Tyr Asp Val Leu Gln Ile 1205 1210 1215Lys Lys Tyr Tyr Glu Lys Thr
Thr Tyr Asn Cys Gln Ile Leu Cys 1220 1225 1230Glu Lys Asp Thr Lys
Thr Phe Gly Leu Phe Gly Ile Gly Lys Phe 1235 1240 1245Val Lys Asp
Tyr Gly Tyr Val Trp Asp Thr Tyr Asp Asn Tyr Phe 1250 1255 1260Cys
Ile Ser Gln Trp Tyr Leu Arg Arg Ile Ser Glu Asn Ile Asn 1265 1270
1275Lys Leu Arg Leu Gly Cys Asn Trp Gln Phe Ile Pro Val Asp Glu
1280 1285 1290Gly Trp Thr Glu 1295
* * * * *